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ABSTRACT 
 
Chronic obstructive pulmonary disease (COPD) is characterized by airway obstruction 
that is mostly irreversible. The typical features of COPD are chronic inflammation in 
the small airways, with varying degrees of chronic bronchitis and/or emphysema. In the 
Western world, long-term smoking is the major risk factor for COPD. The pathogenesis 
of smoking related airway disease such as COPD has been postulated to be highly 
associated with oxidative stress and protease/antiprotease imbalance. 
 
The diagnosis of COPD is based on spirometry, but the major problem is that the 
diagnosis is often delayed since during its early stages, clear symptoms such as dyspnea 
and coughing are lacking, even though the deterioration of lung function has already 
started. The differential diagnosis of COPD from asthma is especially difficult in 
smokers. There is an urgent need to develop reliable biomarkers that would detect early 
COPD, and which could differentiate the sub-phenotypes of COPD as well as COPD 
from asthma and finally be useful in developing treatment strategies for different 
phenotypes and used in monitoring disease activity and progression. 
 
The first goal of this study was to compare different potential markers in various 
sample types that reflect oxidative stress in the lung, how they are related to each other, 
and to find the most specific markers for the early detection and monitoring of COPD 
and asthma and differentiation of these diseases as well as the disease from the 
condition of the so-called “healthy smoker”. Another goal was to examine the effects of 
smoking cessation on the best potential markers of oxidative and protease burden. 
Recent lung proteomic studies have indicated that SP-A could be potential marker for 
COPD; sputum proteomics was used to find other biomarkers for early COPD. 
 
Induced sputum specimens were obtained from asthmatic children and adults, patients 
with COPD exacerbation, smokers with chronic bronchitis/COPD, smoking asthmatics, 
asymptomatic smokers and non-smoking healthy controls. Plasma samples were 
collected from young non-smokers and smokers and from middle-aged/elderly smokers 
and non-smokers and subjects with stable stage I-III COPD. Sputum and plasma 
samples and lung tissue specimens were taken from non-smokers, smokers and smokers 
with mild to moderate COPD. 
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Inflammatory cell counts were evaluated from sputum cytospins. Nitrotyrosine was 
assessed by immunohistochemistry by counting nitrotyrosine positive cells in 
cytospins. FeNO measurements were performed using a chemiluminescence analyzer. 
The levels of 8-isoprostane, MMP-7, -8, -9, TIMP-1, SP-A and SP-D were determined 
by EIA/ELISA methods. Induced sputum was analyzed by cysteine-specific two-
dimensional difference gel electrophoresis (2-D DIGE) and PIGR was further studied in 
sputum, lung tissue and plasma by Western blot, immunohistochemistry/image analysis 
and/or ELISA.  
 
FeNO levels were elevated in mild asthma and eosinophils were elevated in asthmatic 
adults and patients with COPD exacerbation when compared to healthy controls. No 
significant differences were detected in sputum 8-isoprostane levels between subjects 
with mild asthma and healthy controls, but in patients with COPD exacerbation, the 8-
isoprostane levels were greatly increased when compared to healthy subjects. In the 
smoking cessation studies, smokers had elevated levels of all of the investigated 
markers at the baseline compared to non-smokers. Neutrophil counts increased after 3 
months of quitting of smoking in the group of chronic bronchitis/COPD but at 6 months 
neutrophils had returned to the levels of non-smokers. 8-Isoprostane declined 
significantly but the levels of FeNO, nitrotyrosine and MMP-8 did not change 
significantly during 3 months after smoking cessation, although after 6 months, the 
levels of MMP-7, -8 and TIMP-1 decreased to the levels of non-smokers and only 
MMP-9 remained elevated at 6 months of smoking cessation. However, the symptoms 
declined significantly already after 3 months of smoking cessation. The plasma levels 
of SP-A, SP-D, MMP-9, TIMP-1 and the ratio of MMP-9/TIMP-1 were increased by 
long-term smoking and COPD, and SP-A correlated with the extent of airway 
limitation. In proteomic screening of sputum, PIGR was found to be elevated in 
smokers and in mild to moderate COPD, and this was confirmed in lung tissue and 
plasma specimens. 
 
To conclude, it seems that sputum 8-isoprostane is not sensitive enough in detecting 
oxidative stress in mild recent asthma while in COPD it may be useful. After smoking 
cessation, the symptoms decline significantly already after a few months but the 
oxidant and protease burdens seem to persist in the airways for months. SP-A and PIGR 
11 
 
can be proposed as representing new promising markers in smoking related chronic 
inflammation and COPD. 
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INTRODUCTION 
 
Chronic obstructive pulmonary disease (COPD) is an important disease globally 
(Menezes et al. 2005, Xu et al. 2005) and it is predicted that it will cause even more 
disability and death and generating enormous healthcare costs (Sullivan et al. 2000). 
COPD is characterized by chronic inflammation of the peripheral airways, chronic 
bronchitis, destruction of the lung tissue and systemic manifestations (MacNee 2005, 
Pauwels et al. 2001, Rabe et al. 2007). The diagnosis of COPD is often delayed since in 
its early stages, there is a lack of clear symptoms. Changes in lung function are not seen 
until the mainly irreversible lung damage is already extensive. In addition, even though 
spirometry can be used in the assessment of disease severity, it does not reflect its 
activity.  
 
Cigarette smoking is the main risk factor for COPD (Fletcher and Peto 1977, Rabe et al. 
2007). Cigarette smoke contains billions of reactive oxygen species (ROS) (Church and 
Pryor 1985), which trigger a major inflammatory response in the airways and activate 
many proteases (Kawikova et al. 1996, Rahman and MacNee 1998, Wood et al. 2003). 
Oxidant/antioxidant and protease/antiprotease imbalances further contribute to chronic 
airway inflammation causing damage to lung tissue and obstruction of the airways 
(Dhami et al. 2000, Janoff and Carp 1977, Wright and Churg 2008).   
 
The differentiation of COPD from asthma is challenging especially in smokers since 
smoking modifies the typical asthmatic inflammation towards the characteristics that 
can be seen in smoke-related airway inflammation and pathology. Smoking asthmatics 
are often excluded from experimental studies and not many studies have compared 
potential non-invasive markers in samples taken from patients with COPD and asthma. 
Only a few studies exist on the effects of smoking cessation on airway 
inflammation/pathology. At present, there is no valid method for detecting early COPD 
although biomarker research is vigorously seeking non-invasive tools for disease 
detection, differentiation of sub- phenotypes and the disease of “healthy” smokers and 
COPD from those with asthma and for disease follow-up. Fractional exhaled nitric 
oxide (FeNO) has been widely used in detecting allergic asthma, but the corresponding 
sensitive/specific markers for early COPD have still to be discovered. Proteomic 
screening of sputum has offered a new non-hypothesis driven approach for biomarker 
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research and has already revealed several potential markers for COPD, which require 
further investigation (Ishikawa et al. 2010, Ohlmeier et al. 2010, Ohlmeier et al. 2008). 
 
Several studies exist about FeNO in asthma, which appears to be sensitive in detecting 
oxidative/nitrosative stress in asthmatic airways and to correlate with the extent of 
eosinophilic inflammation and with several markers of asthma control (Kharitonov and 
Barnes 2001b, Sippel et al. 2000, Smith et al. 2005). The levels of FeNO are not 
changed in stable COPD (Kharitonov and Barnes 2001a, Rytila et al. 2006) but increase 
during exacerbations (Maziak et al. 1998). FeNO is not however specific to asthmatic 
inflammation (Kharitonov and Barnes 2001a) and generally decreases in smokers 
(Maziak et al. 1998, Rytila et al. 2006), so it is not reliable for the diagnosis of asthma 
in smokers. 
 
8-Isoprostane has been proposed to represent a reliable marker for oxidative stress in 
lung diseases (Montuschi et al. 2004). Elevated 8-isoprostane levels have been reported 
in exhaled breath condensate (EBC) and sputum samples from asthmatics (Baraldi et al. 
2003a, Montuschi et al. 1999) and COPD patients and from the sputum of smokers 
(Kinnula et al. 2007, Kostikas et al. 2003, Montuschi et al. 2000).  
 
Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) have an 
important role not only in tissue repair but also in the pathogenetic processes in both 
COPD and asthma (Kelly and Jarjour 2003, Parks and Shapiro 2001). Oxidants present 
in cigarette smoke contribute to MMP activation (Kinnula 2005a). COPD patients have 
increased levels of sputum MMP-1, -8, -9 and -12 (Beeh et al. 2003, Culpitt et al. 2005, 
Demedts et al. 2006, Elkington and Friedland 2006, Vernooy et al. 2004). 
 
The surfactant proteins A- and D (SP-A and SP-D) have critical roles in pulmonary 
defence (Mason et al. 1998, Whitsett 2005). SP-A is elevated in plasma/serum and 
sputum samples of smokers and COPD patients (Behera et al. 2005, Kida et al. 1997, 
Kobayashi et al. 2008, Mazur et al. 2011, Nomori et al. 1998, Robin et al. 2002). A 
recent proteomic study on lung tissues identified SP-A as a potential marker for COPD 
(Ohlmeier et al. 2008). There are controversial reports about the significance of SP-D in 
smokers and COPD (Kobayashi et al. 2008, Lomas et al. 2009, Ohlmeier et al. 2008, 
Winkler et al. 2011). 
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Polymeric immunoglobulin receptor (PIGR) is proposed to be a potential regulator of 
specific immune defence and inflammation (Wines and Hogarth 2006). Decreased 
PIGR expression in the airway epithelium from subjects with severe to very severe 
COPD (Stage III-IV) patients have been reported (Pilette et al. 2001, Polosukhin et al. 
2011), but the role of PIGR in the development of COPD or in early COPD is 
unknown. 
 
The present study investigated potential non-invasive oxidant markers in different 
sample types e.g. sputum, plasma, exhaled air and lung tissue in order to find markers 
for early diagnosis of COPD and to differentiate “healthy” smokers from the disease. In 
study I, the value of sputum and EBC 8-isoprostane was assessed in recently diagnosed 
children and adults with mild asthma. In studies II and III the effects of smoking 
cessation on sputum neutrophils, 8-isoprostane, nitrotyrosine, matrix metalloproteinases 
(MMP-7, -8, -9), TIMP-1 and FeNO was investigated in asymptomatic smokers and 
patients with chronic bronchitis/COPD or asthma. In study IV, the potential effects of 
ageing and smoking to the levels and relationships between plasma SP-A, SP-D, MMP-
9 and TIMP-1 were determined. In study V, non-hypothesis driven non-biased 
proteomics was used to seek new potential markers from sputum for early COPD. 
Based on these findings PIGR was chosen for further investigations and to study if the 
elevation of PIGR in sputum from smokers and patients with COPD could be observed 
also in lung tissue and plasma samples. 
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REVIEW OF THE LITERATURE 
 
1. Chronic obstructive pulmonary disease (COPD) and asthma 
 
1.1 Classification and clinical features of COPD and asthma 
 
According to Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
Guidelines (Pauwels et al. 2001) COPD is defined as a disease state characterized by 
airflow limitation that is not fully reversible and usually is progressive. Characteristic 
features of COPD include chronic inflammation in the small airways, with varying 
degrees of chronic bronchitis and destruction of the lung parenchyma (emphysema). 
Due to the tissue destruction, there are also abnormalities in gas diffusion (MacNee 
2005, Pauwels et al. 2001, Rabe et al. 2007). It varies whether the patient has one or 
several of these conditions. COPD is also characterized by exacerbation phases often 
triggered by viral and/or bacterial infections when the patients usually suffer from 
increased cough, sputum, dyspnea and they may require treatment with antibiotics 
and/or steroids and be hospitalized (Celli and MacNee 2004a).  
 
Cigarette smoke induces mucous gland enlargement and goblet cell hyperplasia leading 
to increased mucus secretion and cough, the main symptoms of chronic bronchitis 
(Hogg 2004a). Chronic inflammation in the small airways is associated with several 
abnormalities including smooth muscle hypertrophy, excess mucus secretion, oedema 
and infiltration of several inflammatory cells. It has been postulated that airway 
remodeling with fibrosis plays a crucial role in the narrowing of the small airways 
leading to airway obstruction in COPD patients (Hogg et al. 2004b, Wright 1995). 
Emphysematous lung is characterized by enlarged and/or destroyed airspaces and 
airway walls and also by the local presence of fibrotic lesions especially in the small 
airways and in some areas of lung parenchyma (Snider et al. 1985). 
 
COPD is increasingly being accepted as a systemic disease since it exhibits also many 
systemic co-morbidities (GOLD 2011) i.e. cardiovascular diseases, persistent systemic 
inflammation, nutritional abnormalities and weight loss, exercise intolerance, 
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osteoporosis and depression (Agusti and Soriano 2008, Fabbri and Rabe 2007, Jones 
and Agusti 2006, MacCallum 2005). 
In the Global Initiative for Asthma (GINA) Guidelines (GINA 2009), asthma is defined 
as a chronic inflammatory disorder of the airways in which many cells and cellular 
elements play a role. The chronic inflammation evokes an associated increase in airway 
hyperresponsiveness leading to recurrent episodes of wheezing, breathlessness, chest 
tightness and coughing, especially at night or in the early morning. These episodes are 
usually associated with widespread but variable airflow obstruction that often is 
reversible, either with treatment or spontaneously.  
 
1.2 Inflammatory profiles of COPD and asthma 
 
There are many studies and reviews on the inflammatory profile in COPD and asthma 
(Chanez et al. 1999, Gibson et al. 1999, Jeffery 1999, Keatings and Barnes 1997, Kirby 
et al. 1987, Loh et al. 2005, NHLBI/WHO 2002, Saetta 1999, Tetley 2005, van 
Aalderen et al. 1999, Walters and Gardiner 1992). COPD is characterized by airway 
inflammation with neutrophil predominance (Bosken et al. 1992) and periods of acute 
exacerbations (Fletcher and Peto 1977) with further worsening of lung function and 
more severe airway inflammation (Gompertz et al. 2001). Exacerbations are often 
triggered by viral and/or bacterial infections, which increase the numbers not only of 
neutrophils but also eosinophils and activated macrophages in the airways (Rahman and 
MacNee 2000, Saetta et al. 2001).  
 
In asthma, airway inflammation is present in all forms, even in mild (Battaglia et al. 
2005) and asymptomatic cases (Bousquet et al. 2000, Montuschi et al. 2004) and it is 
present in both central and peripheral airways (Hamid et al. 1997). A strong association 
is seen between fractional exhaled nitric oxide (FeNO) and skin prick test scores, total 
IgE levels (Ho et al. 2000) and eosinophilic airway inflammation (Silvestri et al. 1999, 
Piacentini et al. 1999, Payne et al. 2001, Jones et al. 2001). Neutrophil accumulation is 
a typical feature also in asthma exacerbations (Fahy et al. 1995, Kim et al. 2000). An 
overlapping in the inflammatory profiles and also in oxidant markers is seen especially 
in acute asthma and COPD exacerbation.  
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Cigarette smoke induces macrophages and polymorphonuclear leukocytes to produce 
more ROS, leading to the recruitment of further leukocytes into the airways (Hoidal 
and Niewoehner 1982, Niewoehner et al. 1974). It appears that in smokers with asthma 
there are features of both accelerated and suppressed inflammatory responses, but 
generally, the cell profile seems to change to the situation seen in COPD. In these 
individuals the levels of sputum eosinophils are decreased (Chalmers et al. 2001), 
possibly partly due to the exogenous NO in cigarette smoke that is known to trigger 
apoptosis of activated eosinophils (Assreuy et al. 1993) whereas the numbers of 
neutrophils are elevated (Chalmers et al. 2001). Many asthmatic smokers display mixed 
features of typical asthmatic and smoke-related airway inflammation and pathology. 
Symptoms and lung function tests are only indirect ways to assess the disease severity 
in both COPD and asthma and they do not reveal the extent of the underlying airway 
pathology. Smoking alone has several effects on the airways and there is a need to 
clearly separate the effects of smoking from the disease and its progression. 
 
1.3 Epidemiology and etiology of COPD and asthma 
 
The prevalence of COPD is approximately 10% in the general population (Menezes et 
al. 2005, Xu et al. 2005) but it is projected to increase globally as smoking frequencies 
rise and the population ages (Murray and Lopez 1997, Feenstra et al. 2001) generating 
even higher healthcare costs (Sullivan 2000). A recent study reported a COPD 
prevalence of 5% in Finland and it showed an association with low economic status 
(Kanervisto et al. 2011) but the incidence of COPD does not seem to be increasing 
anymore (Vasankari et al. 2010) and in fact both hospitalization and costs due to COPD 
are declining in Finland (Kinnula et al. 2011). Importantly, in global terms, COPD is an 
increasing cause of chronic disability and is indeed estimated to become the fifth 
commonest cause of chronic disability throughout the world by 2020 (Lopez 2006). 
The Global Burden of Disease studies ranked COPD in 1990 as the sixth commonest 
cause of death worldwide and it is predicted that it will have risen to third place by 
2020 (Lopez 2006). In addition, the World Health Organization predicted that COPD 
will rise from its current ranking as fifth commonest reason of death to be the fourth 
commonest by 2030 behind only cerebrovascular disease, ischemic heart disease and 
HIV/AIDS (Mathers and Loncar 2006). 
18 
 
Especially in the Western world, COPD is strongly associated with cigarette smoking 
(Culpitt and Rogers 2000, Scanlon et al. 2000); 90% of COPD patients are smokers. 
There are older studies suggesting that only 10%-15% of smokers develop COPD 
(Fletcher and Peto 1977). However, the results from more recent large epidemiological 
studies indicate that the risk may be nearly 50% (Lundback et al. 2003). Not all 
smokers develop clinically significant COPD suggesting that there must be 
environmental and genetic factors which can modify the risk for each individual 
(Fletcher and Peto 1977, Smith and Harrison 1997). The best documented genetic risk 
factor is a severe deficiency of α1-antitrypsin (Stoller and Aboussouan 2005). Globally 
other risk factors include environmental and indoor biomass smoke, occupational dusts, 
chemicals and pollution (Rabe et al. 2007, Viegi et al. 2001). The symptoms generally 
emerge in middle-age but can also become earlier since smoking is being initiated 
earlier and earlier (13-15 years old) and the development of COPD requires a minimum 
of 10-15 years smoking history. 
 
Worldwide, the prevalence of asthma can range from 1% up to 18% in the populations 
in different countries (Masoli et al. 2004, Urrutia et al. 2007); in Finland, the 
prevalence is approximately 6% and it is increasing but the burden of asthma in terms 
of hospital days and chronic disability has decreased considerably (Haahtela et al. 
2006). Asthma is a complex inflammatory disorder caused by the interaction of several 
environmental factors and multiple genes (Umetsu et al. 2002, von Mutius 2009). Risk 
factors for asthma include history of allergies and/or atopy, a family history of asthma, 
a low birth weight and exposure to tobacco smoke or pollution/environmental toxins 
(Robays et al. 2009, Pichavant et al. 2008, Haby et al. 2001). Exposure to tobacco 
smoke increases the risk of asthma especially when exposure occurs during pregnancy 
and in early childhood (Haahtela et al. 2008, Elliot et al. 2003, OEHHA 2005) but also 
in adults (Jaakkola and Jaakkola 2002, Jaakkola et al. 2003, Larsson et al. 2003). 
 
1.4 Diagnosis of COPD and asthma 
 
Spirometry is essential for COPD diagnosis; according to GOLD criteria the post-
bronchodilator FEV1/FVC is below 0.70 in COPD (GOLD 2011). The characteristic 
symptoms of COPD include chronic and progressive cough, dyspnea and sputum 
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production and usually the patient has a long smoking history or other prolonged 
exposure to risk factors. Coughing and sputum production may occur many years 
before the development of airflow limitation offering a unique opportunity to identify 
smokers who are at risk of developing COPD (Rabe et al. 2007). On the other hand, 
subjects with COPD may consider themselves asymptomatic without any signs of the 
disease (Toljamo et al. 2010). Most patients only tend to seek help when lung function 
deterioration has already started since there are no significant symptoms in the early 
stages of COPD. 
 
In asthmatic patients, the clinical diagnosis is indicated by symptoms such as episodic 
breathlessness, wheezing, cough and chest tightness (Levy et al. 2006). An atopic 
history, episodic symptoms after allergen exposure, seasonal variability of symptoms 
and asthmatic individuals in the family may also be helpful diagnostic tips. Significant 
bronchial variability is a characteristic of asthma and is defined as a reduction in the 
post-exercise peak expiratory flow (PEF) and/or forced expiratory volume in 1 second 
(FEV1) of  15% of the pre-exercise value (ATS 2000), or in spirometry, improvement 
of FEV1  12% and at least 200ml after a bronchodilating drug or a provocative 
concentration of histamine causing a 15% fall in FEV1 (PD15FEV1) < 0.4mg in 
histamine challenge test (Sovijarvi et al. 1993, ATS 2000), or  20% diurnal variation 
in the PEF values and/or at least  15% improvement in PEF after a dose of 
bronchodilator during home recording.  
 
1.5 COPD/asthma overlapping  
 
COPD and asthma both are chronic inflammatory lung diseases and in both conditions, 
inflammation is associated with structural alterations in the airways (Jeffery 2004, 
Guerra 2005). Despite their distinct clinical features, a considerable overlap in 
symptoms and pathogenesis is seen. This can lead to a phenotypic overlap or a mixed 
syndrome with characteristics of both diseases (Kim and Rhee 2010). Several studies 
have reported partial reversibility after short-term and long-term bronchodilator 
administration in COPD patients (Mahler et al. 1999, Donohue et al. 2002). The current 
guidelines also depict a fixed or irreversible component to the airway obstruction in 
some asthma patients (GINA 2009).  
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Alveolar inflammation and emphysema are characteristics of COPD but alveolar 
inflammation has also been detected in asthma though it is classically considered as a 
chronic inflammatory disease of the airways (Bousquet et al. 1996). The “Dutch 
hypothesis” postulates that asthma and COPD are simply different expressions of a 
single disease entity (Vestbo and Prescott 1998), but the “British hypothesis” states that 
asthma and COPD are separate clinical entities with similar symptoms (Lange et al. 
1998), although the general consensus is that similar pathogenetic mechanisms are 
involved in both diseases (Kim and Rhee 2010). 
 
The differentiation between the inflammatory profiles of asthma and COPD may be 
challenging in some cases. Classically, asthma is associated with a prominence of 
eosinophils, CD4+ lymphocytes and macrophages whereas increases in neutrophils, 
macrophages and CD8+ T-cells are seen in the airways of COPD patients (Kim and 
Rhee 2010). The differentiation of asthma from COPD is especially difficult in 
smokers. In smokers aged 30 to 40 years, clinical and pathologic manifestations 
resembling early-stage COPD may already be present, indicative of mixed or 
intermediary condition (Boulet et al. 2006). The prevalence of active smoking in 
asthmatic individuals is as common as in the general population; in Finland for example 
as many as 30% of asthmatics are smokers (Haahtela et al. 2006). Smoking asthmatics 
are frequently excluded from experimental studies and thus there is limited data about 
the airway pathology of smoking asthmatics. Asthmatics who smoke show higher 
numbers of neutrophils in BAL fluid and lung tissue (Wenzel et al. 1997, Louis et al. 
2000). Conversely, in COPD exacerbations, tissue eosinophilia is common (Saetta et al. 
1994). 
 
Overall, an overlap in clinical features is often seen in COPD and asthma, but they are 
considered as distinct conditions whose differences affect both management and 
prognosis. The assessment of the patient’s clinical history, current symptoms, lung 
function tests and usage of radiology and cellular markers of inflammation may help in 
differentiating COPD from asthma (Kim and Rhee 2010).  
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Table 1. The main classical differences between COPD and asthma. 
In reality, there is extensive overlapping in these diseases. 
 
  COPD ASTHMA 
Airflow limitation 
 
Usually progressive, 
mostly irreversible 
Widespread but 
variable, usually 
reversible          
Airway hyperreactivity Mild to no Yes 
Bronchodilator response Mild to no Yes 
Corticosteroid response Mild to no Yes 
Long-term smoking history Usually No 
Association with atopy No Often 
Onset (typical) Middleage/older Childhood/Middleage 
 
Location of inflammation 
in the lung 
Small airways, lung 
parenchyma, alveolar 
region Airways 
Parenchymal destruction Yes No 
Diffusion capacity Normal/worsened Normal 
Extrapulmonal 
manifestations Yes  No 
Main inflammatory cells 
Neutrophils, macro- 
phages, CD8+ 
Eosinophils, mast cells,  
CD4+ 
Prognosis 
Increased disability and 
morbidity Usually good 
 
Modified from Bleecker 2004, Zeki et al. 2011. 
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1.6 Effects of smoking cessation in the airways of COPD and asthma 
 
Smoking cessation is the only effective way to reduce COPD morbidity, hospital 
admissions (Godtfredsen et al. 2002) and COPD progression (Rabe et al. 2007). 
However, the effects of smoking cessation programs and guidance in order to break of a 
habit of smoking are limited and success rates vary around 5-15% (Kaper et al. 2005, 
Stratelis et al. 2006, Tashkin et al. 2001). It has been reported that as the disease 
becomes more severe, giving up smoking has only a marginal effect on its progression 
(Scanlon et al. 2000). Smoking is also an important contributor to asthma pathogenesis. 
Smoking asthmatics tend to have more severe disease than non-smoking asthmatics, 
their inflammatory features are different to those individuals with typical asthma and 
their symptoms and inflammation are rather resistant to corticosteroid therapy (Siroux 
et al. 2000). Several cross-sectional studies have been conducted on smokers, ex-
smokers and patients with COPD, but only a few longitudinal studies have assessed the 
long-term effects of smoking cessation (Chaudhuri et al. 2006, Willemse et al. 2005). It 
is not known in detail how the airway inflammatory processes change after smoking 
cessation in chronic smokers with or without COPD or asthma. 
 
One study analyzed pooled data from three bronchial studies and concluded that several 
airway inflammatory cells, including CD4+ and CD8+ lymphocytes were rather similar 
in current and ex-smokers (Gamble et al. 2007). Evidence of ongoing inflammation has 
been documented via the increased levels of neutrophils and eosinophils in BAL fluid 
and sputum and eosinophilic cationic protein (ECP) in sputum from COPD patients 
who do not currently smoke (Lapperre et al. 2006). The persistence of elevated sputum 
neutrophils and lymphocytes even after one year of smoking cessation has been 
reported (Willemse et al. 2005). However, in asthmatics, sputum neutrophils are 
reduced after six weeks of quitting of smoking (Chaudhuri et al. 2006). 
 
1.7 Treatment strategies for COPD and asthma 
 
Pharmacologic therapy is used to prevent and control symptoms, to reduce the severity 
and frequency of deterioration phases and to improve health status and exercise 
tolerance. However, there are no medications for COPD that would prevent the long-
term decline in lung function (Anthonisen et al. 1994, Burge et al. 2000, Pauwels et al. 
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1999). Short-acting bronchodilators (e.g. short-acting beta2-agonists and 
anticholinergics) are recommended as short-term therapy in COPD patients and 
treatment with long-acting bronchodilators (e.g. anticholinergics, beta2-adrenergic 
agonists, theophylline) using one or more of these medications to control symptoms is 
usually recommended in COPD patients in whom short-acting beta2-agonists do not 
provide sufficient relief (GOLD 2011). Inhaled corticosteroid treatment (ICS) is used in 
combination with a long-acting bronchodilator in patients with severe to very severe 
COPD (stages III-IV) who have severe or frequent exacerbations (GOLD 2011). 
However, COPD patients exhibit a poor response to corticosteroids and it has been 
shown that there may even be active resistance against the anti-inflammatory actions of 
steroids (Barnes 2006). Oral corticosteroids and antibiotics are used mainly in COPD 
exacerbations.  
 
Roflumilast is the newest medication in COPD treatment. It is a phosphodiesterase-4 
(PDE-4) inhibitor that reduces inflammation by inhibiting the breakdown of 
intracellular cyclic AMP (Giembycz and Field 2010), which in turn is an important 
intracellular signal for a diverse array of cytokines, hormones, neurotransmitters and 
medications that stimulate membrane-bound adenyl cyclase (Bender and Beavo 2006). 
It has been reported that roflumilast can reduce exacerbations especially in patients 
with severe to very severe COPD and that it improves FEV1 in patients treated with 
salmeterol or tiotropium (Calverley et al. 2009, Fabbri et al. 2009). 
 
Controlled oxygen support may be used in advanced cases of COPD (Calverley 2003, 
GOLD 2011) and some highly selected COPD patients may benefit from surgery: lung 
volume reduction, bullectomy or even lung transplantation (Pauwels et al. 2001). 
 
In contrast to COPD, anti-inflammatory drugs, such as ICS are used successfully in 
asthma therapy (Juniper et al. 1990). Other medications commonly used in asthma 
include leukotriene modifiers (Dicpinigaitis et al. 2002, Barnes and Miller 2000) that 
are alternatives to ICS in mild asthma (Leff et al. 1998), long-acting inhaled β2-
agonists combined with ICS (Lazarus et al. 2001) and rapid-acting inhaled β2-agonists 
for quick relief of bronchospasm (GINA 2009). Smokers with asthma often show an 
impaired response to asthma medications, leading to impaired asthma control. 
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1.8 Prognosis of COPD and asthma 
 
If diagnosed early enough and if the patient quits smoking, COPD prognosis is 
relatively favourable. However, if smoking continues, then the decline in lung function 
accelerates and may eventually lead to respiratory failure and/or premature death. A 
recent study reported high variability in the rate of decline in FEV1 in COPD patients 
over a period of 3 years; in more than half of the COPD patients the rate of decline in 
FEV1 was no greater than is observed in subjects without lung disease and increase in 
the rate of decline in FEV1 was related to current smoking, emphysema and 
bronchodilator response (Vestbo et al. 2011). The 5-year mortality rate of patients with 
COPD varies from 40 to 70% depending on the disease severity and the major causes of 
death are COPD itself, lung cancer and cardiovascular diseases (Nishimura and 
Tsukino 2000). The symptoms do not closely reflect spirometric changes and they seem 
to predict exacerbation only in some individuals (Seemungal et al. 2000). COPD 
exacerbations are in turn important events in terms of disease progression, morbidity 
and mortality. Many COPD patients never recover completely from an exacerbation. It 
is clear that the two main solutions in preventing the increase of already high burden of 
COPD throughout the world would be a way of detecting COPD early enough that 
symptoms have not appeared and better methods of encouraging these patients to give 
up smoking. 
 
After several years of smoking cessation, the decline rate in lung function becomes 
similar to that of never smokers (Anthonisen et al. 1994). However, the lung function 
lost during the time the patient smoked never fully recovers and COPD patients might 
develop additional symptoms and progress to a more severe disease even after many 
years of smoking cessation (Kohansal et al. 2009). Although the rate of decline in 
FEV1 is a good marker of disease progression and mortality (Anthonisen et al. 1986), it 
does not adequately reflect all the systemic manifestations of the disease. 
 
The BODE index has been developed as a practical tool for measuring a patient’s 
degree of lung impairment and to show how the disease affects the entire body 
negatively by using factors that might predict death (Celli et al. 2004). BODE measures 
body mass index (BMI), airway obstruction (measured by FEV1), dyspnea (measured 
by the MMRC scale) and exercise tolerance (measured by the 6-minute walk test). The 
25 
 
higher the BODE index, the higher is the risk of death (Celli et al. 2004). In general 
practice, such complex estimates are not useful, and simple measures for assessing the 
quality of life are being developed (Jones et al. 2009a, Jones et al. 2009b). 
 
Most children with mild intermittent asthma outgrow their asthma although symptoms 
might return as episodic at an older age (Koh and Irving 2007). In most asthma patients, 
the clinical manifestations of asthma (symptoms, exercise tolerance, impairment of 
lung function and need for rescue medication) can be controlled with appropriate 
treatment and avoidance of allergens and the prognosis is good in these cases (GINA 
2009). When asthma is not treated, or the patient continues to smoke despite the 
asthma, remodeling of the airways might occur, leading to irreversible fibrosis in the 
airways and loss of lung function.  
 
2. Pathogenesis of COPD  
 
The dominant features in COPD are varying degrees of chronic bronchitis and 
emphysema, with some degree of overlapping with asthma, with the common 
phenotype being airflow obstruction. Pathological changes are found in the proximal 
and peripheral airways, lung parenchyma and pulmonary vasculature (Hogg 2004). 
Long-term cigarette smoking is the main risk factor for COPD but also occupational 
exposures to dusts and chemicals as well as genetics contribute to COPD pathogenesis. 
Therefore, the interactions of host factors with the environment are linked to pathologic 
changes and clinical symptoms generating the pathologic triad of COPD: chronic 
inflammation, oxidative stress and protease-antiprotease imbalance (Fischer et al. 
2011). Together these mechanisms result in mucous cell metaplasia and hyperplasia, 
hypersecretion of mucous, airway fibrosis, smooth-muscle alterations, and lung tissue 
destruction (Wright and Churg 2008). 
2.1 Chronic inflammation 
 
Long-term tissue damage and acute inflammation induced by cigarette smoke or other 
noxious particles contribute to the switch to a chronic, persistent inflammation of the 
lung (Oudijk et al. 2003). Neutrophils, macrophages, T- lymphocytes and also 
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eosinophils and mast cells have all been linked to chronic bronchitis or COPD 
(O'Donnell et al. 2006). 
 
2.1.1 Key inflammatory cells 
 
2.1.1.1 Neutrophils 
 
Neutrophils are the main inflammatory cells at the site of acute inflammation and they 
are recruited to the airways and lung parenchyma from the circulation via adhesion 
molecules allured by chemotactic factors (Barnes et al. 2003). Nicotine itself may also 
act as a chemoattractant for neutrophils (Totti et al. 1984). Neutrophils secrete many 
proteases, such as neutrophil elastase, proteinase-3, cathepsin G and MMPs -8 and -9 
which are potent mucus stimulants and contribute to alveolar destruction and tissue 
damage (Barnes 2004, Barnes et al. 2003). Increased numbers of activated neutrophils 
can be found in bronchial biopsies, sputum and BAL fluid of smokers (Willemse et al. 
2005) and COPD patients (Keatings et al. 1996, Lacoste et al. 1993) but only a 
relatively minor elevation in the airways and parenchyma (Finkelstein et al. 1995). The 
neutrophil numbers in both bronchial biopsies and induced sputum correlate with 
COPD disease severity (Di Stefano et al. 1998, Keatings et al. 1996) as well as with the 
rate of decline in lung function (Stanescu et al. 1996). 
  
2.1.1.2 Macrophages 
 
Macrophages are phagocytic for bacteria and thus have an important role in host 
defence. Macrophages appear also to have a crucial role in the pathophysiology of 
COPD (Shapiro 1999). The numbers of macrophages are increased in airways, lung 
parenchyma, sputum and BAL fluid in COPD patients (Barnes et al. 2003, Di Stefano 
et al. 1998, Saetta et al. 1993, Tetley 2002) and those numbers correlate with the 
severity of COPD (Di Stefano et al. 1998). The increase in the numbers of macrophages 
might be due to the increased recruitment of monocytes from the circulation in response 
to monocyte-selective chemokines (Capelli et al. 1999, Traves et al. 2002), but also due 
to increased prolonged survival of macrophages in smokers and COPD patients (Tomita 
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et al. 2002). Cigarette smoke stimulates macrophages to release inflammatory 
mediators, such as TNF-α and IL-8, chemotactic factors, proteolytic enzymes and ROS 
(Punturieri et al. 2000, Russell et al. 2002). Corticosteroids seem to be rather ineffective 
in suppressing inflammation, including the elevations in the proteases, cytokines and 
chemokines encountered in COPD patients (Culpitt et al. 1999, Keatings et al. 1997). In 
COPD patients and to some extent also in smokers without COPD, the macrophages are 
resistant to the actions of the corticosteroids, which may be explained by the major 
decline in the expression of histone deacetylase (HDAC) (Ito et al. 2001), which 
normally switches off inflammatory genes and thus reduces cytokine release (Ito et al. 
2000).  
 
2.1.1.3 Lymphocytes 
 
The numbers of T-lymphocytes, especially CD8+ but also CD4+, are increased in lung 
parenchyma and in both central and peripheral airways of patients with COPD 
(Finkelstein et al. 1995, Majo et al. 2001, O'Shaughnessy et al. 1997, Saetta et al. 
1999). The role of T-cells in the pathophysiology is still not clear, but the numbers of 
T-lymphocytes correlate with the amount of alveolar destruction and the severity of 
airflow obstruction (Majo et al. 2001). CD8+ cells can trigger cytolysis and apoptosis 
of alveolar epithelial cells by releasing perforins, TNF-α and granzyme-B (Hashimoto 
et al. 2000). The mechanisms by which T-cells accumulate in the airways and lungs of 
COPD patients are still unclear but homing seems to require the presence of some kind 
of triggering factor and after which there is adhesion and selective chemotaxis (Barnes 
et al. 2003). The numbers of CD8+ and T-helper type 1 CD4+ cells are increased in the 
circulation of COPD patients (de Jong et al. 1997, Kim et al. 2002, Majori et al. 1999). 
This suggests that there might be some kind of chronic stimulation via antigens 
presented via the HLA Class 1 pathway. Dendritic cells can migrate to regional lymph 
nodes from the airways and stimulate the proliferation of T-lymphocytes (Barnes et al. 
2003). CD8+ cell numbers are commonly elevated in airway infections and it may be 
that the chronic colonisation by bacterial and viral pathogens in the airways of COPD 
patients is responsible for this inflammatory response (Cosio and Majo 2002). In 
addition, protease-induced lung damage may reveal normally isolated autoantigens or it 
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may be that cigarette smoke itself causes injury to airway epithelial cells making them 
antigenic (Cosio and Majo 2002).  
 
2.1.1.4 Eosinophils 
 
Eosinophils are most commonly seen in asthma. However some studies have reported 
increased numbers of eosinophils and eosinophil cationic protein (ECP) in the sputum 
and BAL fluid from stable COPD patients (Brightling et al. 2005, Fujimoto et al. 1999, 
Lacoste et al.1993, Pizzichini et al. 1998), with a further increase occurring during 
COPD exacerbations in which the increase is at least partially related to viral infections 
(Papi et al. 2000, Rohde et al. 2004, Saetta et al. 1994). The presence of eosinophils in 
COPD patients presumes that a response will be obtained to corticosteroids and may 
indicate the coexistence of asthma (Brightling et al. 2000, Papi et al. 2000). Eosinophils 
generate ROS, which in turn leads to an increased inflammatory response producing 
asthma-like symptoms.  
 
2.2 Oxidant/antioxidant balance 
 
Reactive oxygen species (ROS) and nitrogen species (RNS) are produced endogenously 
by several cell types, the most potent generators being eosinophils and neutrophils 
which are abundant both in COPD and asthma (Kinnula 2005b, Kinnula et al. 1995). 
The burden of ROS/RNS is increased further by exogenous factors, mostly cigarette 
smoke and environmental agents. One puff of cigarette smoke contains billions of free 
radicals (Church and Pryor 1985). These ROS have multiple effects i.e. activation of 
proteases, elevation in mucus secretion, evoking airway smooth muscle contraction, 
airway hyperresponsiveness, and transcription of many inflammatory genes (Kawikova 
et al. 1996, Rahman and MacNee 1998). The major sites of oxidative attack in COPD 
are the small airways, lung parenchyma and alveolar region. Outside the lung, tissue 
oxidative stress can have systemic effects when ROS leak into the circulation or 
indirectly by inducing stress-related products e.g. cytokines (MacNee and Rahman 
2001). 
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The oxidants present in cigarette smoke stimulate alveolar macrophages to further 
produce ROS (O2
and OH) worsening the vicious cycle by releasing many potent 
mediators, some of which attract neutrophils and other inflammatory cells into the 
lungs of COPD patients (GOLD 2011) which then can generate even more ROS via the 
NADPH oxidase system. Similarly, elevated xanthine oxidase levels found in BAL 
fluid and plasma from COPD patients can increase O2
 and lipid peroxide levels 
(GOLD 2011). Therefore, oxidants may play a key role in initiating or triggering the 
underlying inflammation seen in pathogenesis of COPD.  
 
Many oxidants are unstable and have very short half-lives and therefore their 
measurement is difficult. Hydrogen peroxide (H2O2) is formed from superoxide mainly 
by inflammatory cells and directly involved in several reactions. NADPH oxidase is 
one of the key superoxide generating enzymes that is expressed both in phagocytic and 
non-phagocytic cells (Jones et al. 2000). Endogenous NO is derived from L-arginine by 
at least three different isoforms of NOS (Nathan and Xie 1994). Two of these forms are 
expressed constitutively (NOS1, NOS3) but the inducible form (iNOS, NOS2) is 
activated by inflammatory cytokines. Inducible NOS is responsible for generating the 
majority of NO seen in inflammatory states, being induced by cytokines and expressed 
in inflammation e.g. neutrophils and in non-phagocytic cells (Barnes and Belvisi 1993). 
When ROS are generated, they immediately attack membrane lipids leading to the 
generation of lipid peroxidation products like isoprostanoids, malondialdehyde and 4-
HNE. These markers have been widely investigated in assessing oxidative stress in the 
lung (Kharitonov and Barnes 2001a, Paredi et al. 2002) but a major limitation with 
most of these end products is their poor specificity and reproducibility in different 
diseases that are related to oxidative stress and that they have been generally assessed 
only in moderate/severe COPD. 
 
The oxidant burden in COPD is not only associated with cigarette smoke/environmental 
oxidants and activation of several oxidant generating enzymes. The imbalance is further 
worsened due to decline of the major antioxidant defence in the lung. Complex 
antioxidant machinery of the lung contains various low molecular weight antioxidants, 
metal binding proteins, mucus glycoproteins and several specific antioxidant enzymes 
(Kinnula 2005a and 2005b, Kinnula and Crapo 2003, Kinnula et al. 1995). Generally 
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many protective antioxidant enzymes are first induced by cytokines and oxidative 
stress, which leads to protection but the same enzymes are subsequently inactivated due 
to persistent severe oxidative stress by complex oxidation/nitrosylation and proteolytic 
reactions (Kinnula and Crapo 2003). It has been reported also that the thiol antioxidant 
glutathione (GSH) and its biosynthesizing key enzyme, glutamate cysteine ligase 
(GCL), are decreased in the airways and macrophages of smokers when compared to 
non-smokers (Harju et al. 2002). Furthermore, a deficiency of the major parenchymal 
superoxide scavenging enzyme extracellular superoxide dismutase (ECSOD) leads to 
emphysema (Yao et al. 2010) and this enzyme declines in the lung of severe COPD 
(Regan et al. 2011). Additionally, a deficiency of the major regulator/inducer of several 
antioxidant/detoxification enzymes, nuclear factor erythroid-derived 2-like 2(Nrf2) and 
both Sirtuin 1 and Forkhead box class O 3a (FOXO3) leads to emphysema in mice and 
they also disappear in severe COPD (Hwang et al. 2011). Overall, there is limited data 
about biomarkers of oxidative stress in COPD/asthma, and little is known about the 
relative importance of the various antioxidant pathways and specific oxidant 
biomarkers in COPD.  
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Figure 1. Cigarette smoke and several inflammatory cells lead to generation of 
ROS/RNS in the lung that cause cell and tissue injury. O2−: superoxide; H2O2: 
hydrogen peroxide; NO· : nitric oxide; iNOS: inducible nitric oxide synthase; ONOO-: 
peroxynitrite; GSH: gluthathione; SODs: superoxide dismutases (MnSOD, ECSOD, 
CuZnSOD); MPO: myeloperoxidase; HOCl: hypochlorous acid; OH·: hydroxyl radical; 
H2O: water; GPXs: glutathione peroxidases; CAT: catalase. 
 
 
 
 
Modified from Kinnula and Crapo 2003 and Jaber et al. 2005. 
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2.3 Protease/antiprotease balance 
 
Smoking-induced emphysema is thought to be mediated partly by the prolonged and 
direct inhibition of antiproteases in the lung tissue (Dhami et al. 2000, Janoff and Carp 
1977). Proteases are important factors in pulmonary defence but “spilling” of these 
enzymes can lead to host tissue damage if the inactivation mechanisms are blocked. 
Cigarette smoke or exposure to other smokes can inactivate endogenous antiproteases 
(Cavarra et al. 2001) and trigger an acute pulmonary response that activates alveolar 
macrophages and contributes to the influx of neutrophils into lungs (Fischer et al. 
2011). Long-term smoke exposure causes the continued accumulation of neutrophils, 
macrophages and CD8+ T cells in the lungs (Shapiro 2002). Neutrophils and 
macrophages secrete several proteinases, which act by activating each other or 
inhibiting their endogenous inhibitors, e.g. MMPs degrade α1-antitrypsin and 
neutrophil elastase inhibits tissue inhibitors of MMPs (Fischer et al. 2011, Shapiro 
2002). These enzymes cleave the extracellular matrix, generating chemotactic peptide 
fragments from elastin and collagen for macrophages and neutrophils thus aggravating 
the inflammatory cell accumulation and lung destruction (Fischer et al. 2011, 
Hunninghake et al. 1981, Weathington et al. 2006).  
 
3. Pathogenesis of asthma 
 
Airway inflammation in asthma involves a very complex interaction of several cells, 
mediators, cytokines and chemokines. Immunologic and nonimmunologic 
environmental factors are major triggers of asthma, including viral infections, air 
pollutants such as ozone and cigarette smoke and other cellular mediators (Dworski 
2000). These agents cause activation and influx of inflammatory cells leading to 
generation of inflammatory mediators, which converge to generate ROS, which are 
associated also with the pathogenesis of asthma by evoking bronchial hyperreactivity as 
well as stimulating histamine release from mast cells and mucus secretion from airway 
epithelial cells (Dworski 2000). Thus, while oxidative stress due to smoking is a direct 
causative factor for COPD leading to a further burden of oxidative stress, it is usually a 
secondary effect in asthma subsequent to prior antigenic/allergic challenge of the 
immune cells in lungs. In asthma, the airways are the major site of action, this being 
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characterized by reversible airflow obstruction, airway hyper-responsiveness/ hyper-
reactivity, and chronic inflammation due to the influx of eosinophils and activation of 
inflammatory cells such as macrophages, neutrophils, lymphocytes, and mast cells. 
Airway smooth muscle contraction, increased airway reactivity and secretions, 
increased vascular permeability and increased generation of chemoattractants are the 
major features of the asthmatic response (Hamid et al. 1997). Persistent inflammation, 
epithelial damage and/or aberrant tissue repair mechanisms may lead to structural 
changes of the airway wall, referred to as remodeling (Jeffery 2001, Mauad et al. 2007, 
Broide 2008). Characteristic structural changes include subepithelial fibrosis, smooth 
muscle hypertrophy/hyperplasia, increased deposition of extracellular matrix protein, 
goblet cell hyperplasia, mucus gland hypertrophy and increased angiogenesis (Mauad et 
al. 2007, Broide 2008). The exact immunologic and inflammatory mechanisms leading 
to airway remodeling are still incompletely understood but it is likely that several 
immune and inflammatory cells and mediators are involved in mediating these changes 
(Humbles et al. 2004, Fulkerson et al. 2006). 
4. Need for sensitive and specific biomarkers for early smoking related lung 
disease 
 
It is challenging to evaluate oxidative stress in COPD disease progression. The 
symptoms do not correlate with spirometric changes and the symptoms only predict 
exacerbation in some patients (Seemungal et al. 2000). Spirometry is not very sensitive 
in finding mild disease and does not actually reflect the disease activity. The diagnosis 
of COPD is often delayed, since in its early stages, symptoms are lacking. Many COPD 
patients never recover completely from an exacerbation, i.e. these events are important 
when it comes to disease progression, morbidity and mortality. COPD is not simply one 
disease but instead contains many phenotypes with varying degrees of airway and 
emphysematous changes, meaning that the lung pathology is very complex. All the 
phenotypes are however treated in the same way since no specific biomarkers for the 
differentiation of the disease subtypes or their progression have been identified. Small 
airway inflammation with fibrosis and alveolar destruction are the main 
pathophysiologic events in COPD (Barnes et al. 2006) but at present there is no 
biomarker in clinical practice, which is able to differentiate these conditions from each 
other. Further studies are needed aimed at finding reliable biomarkers that would detect 
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early COPD, differentiate the phenotypes of COPD and identify markers that can be 
used in the assessment of disease progression. There are many studies examining the 
significance of FeNO in asthma (Alving et al. 1993, Byrnes et al. 1997, Kharitonov and 
Barnes 2001b, Kharitonov et al. 1994, Lundberg et al.1996, Nelson et al. 1997, Persson 
et al. 1994) but fewer studies on the other oxidant markers.   
 
Several markers of oxidant burden have been suggested to associate both with the 
pathogenesis and disease progression of asthma (Barnes 1990) and COPD (Repine et al. 
1997). However, given the complexity of oxidative stress and the inflammatory cascade 
and the interaction between these two processes, it is unlikely that measurement of any 
single molecule in the EBC, sputum or biological fluids will be able to provide 
adequate information about disease progression.   
 
5. Biomarker requirements in COPD and asthma 
 
Biomarker research is focusing on developing non-invasive tools for disease detection 
and follow-up. Only totally non-invasive, easily repeatable and practical techniques 
offer these possibilities. The biomarkers themselves will require to have several 
characteristics if they are to be of any use. In addition to sensitivity and specificity, the 
biomarker will need to be cost-effective, stable with minimal day to day or diurnal 
variability and easy to access and analyze. A good biomarker should also provide 
possibilities for early diagnostics, differential diagnosis and monitoring response to 
therapy and for the evaluation of disease progression. It is likely that one biomarker can 
never fulfill these requirements, instead panels or various combinations of biomarkers 
might be the answer and these panels may well be different if they are intended for the 
differential diagnosis of the disease or for following its progression. 
 
6. Problems in measuring oxidative stress in smoking asthmatics 
 
It is problematic to assess the importance of oxidant-related biomarkers especially in 
smoking asthmatics, since smoking per se has significant effects on the levels of FeNO 
and 8-isoprostane. It is also unclear whether these oxidant markers can predict disease 
development in follow-up periods of years or decades. Furthermore, the half-lives of 
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free radicals and oxidants are short, why their direct evaluation is often impossible or 
difficult. 
The airway pathology of smoking asthmatics is still poorly understood since this group 
is frequently excluded from experimental studies. Asthma and cigarette smoking 
potentiate the effects of each other leading to impaired asthma control, more severe 
symptoms (Althuis et al. 1999), increased need for rescue medication (Gallefoss and 
Bakke 2003), accelerated deterioration in lung function (Lange et al. 1998) and reduced 
therapeutic response to corticosteroids (Chalmers et al. 2001, Chaudhuri et al. 2003). 
There is evidence that the time of initiation of smoking might influence the asthma 
phenotype: atopy-associated asthma seems to develop before the start of smoking 
(Raherison et al. 2003). Differential diagnosis from COPD is challenging since 
smoking modifies the typical asthmatic inflammation and asthmatic smokers often have 
features of typical asthmatic and smoke-related airway inflammation and pathology. 
Both accelerated and suppressed inflammatory responses are also seen in smokers with 
asthma. Sputum eosinophils decrease (Chalmers et al. 2001) perhaps due to exogenous 
NO present in cigarette smoke which can increase the apoptosis of activated 
eosinophils (Assreuy et al. 1993) and an elevation in neutrophils is seen (Chalmers et 
al. 2001). Remodeling of airways may also be more severe in asthmatic smokers 
(Carroll et al. 2000). Several markers of oxidative /nitrosative stress are increased even 
in “healthy” smokers.  
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Table 2. The main differences in non-smokers and smokers with asthma. 
In smokers with asthma, both asthma and COPD diagnosis can occur simultaneously. 
 
  NON-SMOKER SMOKER 
Main inflammatory cells Eosinophils Neutrophils 
Asthma control 
Good with appropriate 
medication Impaired 
Symptoms 
Usually in control with 
appropriate medication Often not in control 
Lung function Normal/near to normal Accelerated worsening 
Need for rescue medication Rare Increased 
Response to corticosteroids Good Reduced 
Inflammation in the 
airways Typical asthmatic 
Mixed features of  
asthmatic and smoke-
related 
Airway remodeling Variable More severe 
Prognosis Good 
Increased morbidity 
and mortality 
 
7. Biomarkers of oxidant burden in COPD and asthma 
 
Oxidative/nitrosative stress has generally been assessed by evaluating oxidant 
producing enzymes and their activation, by analyzing markers of protein modifications 
such as protein nitration and carbonylation, by measuring exhaled gaseous metabolites 
related to oxidative/nitrosative stress and by detecting decline/inactivation of small 
molecular weight antioxidants or antioxidant enzymes. 
 
7.1 Oxidant markers 
 
7.1.1 Oxidant generating enzymes 
 
Inducible NOS (iNOS), eosinophil peroxidase (EPO) and myeloperoxidase (MPO) 
represent most widely studied oxidant generating enzymes (Kinnula 2005b). Inducible 
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NOS is the most efficient of the NO synthases in producing NO during inflammation 
and its main location is the airway epithelium but has also been detected in 
inflammatory cells (Barnes and Belvisi 1993). Elevated levels of iNOS in sputum have 
been reported in patients with asthma (Sugiura et al. 2003) but in COPD the iNOS 
levels have been variable (Ichinose et al. 2000, Rytila et al. 2006). The amount of EPO 
is elevated in asthma but MPO, which is expressed in neutrophils and monocytes (Kim 
et al. 2001) is increased in COPD with the levels being higher in COPD than those 
encountered in asthma (Metso et al. 2001). A rather comparable increase in the number 
of MPO positive cells is seen in the induced sputum of chronic non-symptomatic and 
symptomatic smokers with normal lung function who may be at risk of developing 
COPD (Rytila et al. 2006). High variability with large standard deviations has been 
reported in different investigations into sputum MPO concentrations (Kim et al. 2001). 
However, EPO and MPO might have potential significance in differentiating asthma 
from COPD but these have been evaluated only in a few investigations (Metso et al. 
2002a and 2002b). EPO leads to the formation of hypobromous acid (HOBr) and MPO 
to hypochlorous acid (HOCl).  
 
7.1.2 Nitric oxide metabolites 
 
7.1.2.1 Fractional exhaled nitric oxide (FeNO) 
 
Increased FeNO levels have been widely reported in adults (Kharitonov et al. 1994, 
Persson et al. 1994) and children (Byrnes et al. 1997, Lundberg et al. 1996, Nelson et 
al. 1997) with asthma, even in individuals with mild or even no symptoms (Alving et 
al. 1993, Kharitonov and Barnes 2001a). FeNO levels correlate with eosinophilic 
airway inflammation and can predict a decline in asthma control when repeated 
longitudinal measurements are taken (Kharitonov and Barnes 2001b, Liu and Thomas 
2005, Smith et al. 2005). The changes in serial FeNO have a higher predictive value 
than single measurements (Jatakanon et al. 2000, Kharitonov and Barnes 2001b, Leuppi 
et al. 2001). In addition, FeNO is associated with several markers of asthma control, 
such as asthma symptoms, dyspnea score, daily use of medication, and reversibility of 
airflow obstruction (Sippel et al. 2000). An elevation in FeNO levels can be seen before 
any significant decline in airway hyperresponsiveness, elevation of sputum eosinophil 
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levels or changes in lung function parameters (Jatakanon et al. 2000, Kharitonov et al. 
1996a). The main origin of the increased FeNO levels in asthma is the lower airways 
(Kharitonov et al. 1996b). The determination has been shown to be highly reproducible 
in healthy and asthmatic adults and children (Kharitonov et al. 2003). The measurement 
of exhaled NO at different flows reveals that the increase in peripheral NO is often 
related to disease severity (Brindicci et al. 2005). Recent ATS guidelines recommend 
that FeNO measurements could be used as an additional tool for detecting eosinophilic 
airway inflammation i.e. phenotyping asthma, predicting the likelihood of 
corticosteroid responsiveness and to monitor the anti-inflammatory effect (ATS 2011). 
 
However, exhaled NO is somewhat non- specific to asthmatic inflammation; its levels 
increase in viral infections (Kharitonov and Barnes 2001a) and generally decline in 
smokers (Maziak et al. 1998, Rytila et al. 2006). There is also some disagreement on 
whether changes in serial FeNO are significant evidence of loss of asthma control or 
simply due to errors in measurements or to the natural variability of airway 
inflammation over time (Kharitonov 2004). It might be that FeNO is not always related 
to asthma severity or airway inflammation (Kharitonov and Barnes 2000). FeNO 
measurements have remained, despite these problems, as one of the most important 
parameters in the evaluation, treatment and monitoring patients with asthma and airway 
disease with eosinophilic inflammation. 
 
In contrast to asthma, the FeNO levels in stable COPD do not differ significantly from 
controls (Kharitonov and Barnes 2001a, Rytila et al. 2006). However in COPD 
exacerbations, FeNO levels increase (Maziak et al. 1998) most likely due to increased 
oxidative stress, especially in cases where there is coexistent asthma and/or the 
presence of eosinophils (Papi et al. 2000). The increased FeNO levels in unstable 
COPD compared both with stable smokers or ex-smokers with COPD are related 
especially to the presence of eosinophils (Maziak et al. 1998). Since cigarette smoke 
decreases FeNO levels (Kharitonov et al. 1995, Robbins et al. 1996) by down-
regulating NOS3 (Su et al. 1998) and consuming NO, it could be speculated that FeNO 
is not reliable marker for assessing asthma in smokers. FeNO might have importance in 
the differentiation of asthma, eosinophilic bronchitis and COPD but it has only a minor 
role in evaluating COPD. 
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7.1.2.2 3-Nitrotyrosine 
 
The combination of NO and superoxide anion (O2-) in the airways leads to the 
formation of peroxynitrite (ONOO-) which reacts with tyrosine residues of proteins to 
form a stable product, nitrotyrosine (Ischiropoulos et al. 1992). Nitrotyrosine can be 
formed not only by iNOS activation but also by MPO (Davis et al. 2001). Nitrotyrosine 
can be detected in exhaled breath condensate (EBC). Its levels are elevated in asthmatic 
children and adults and decreased in response to corticosteroid treatment (Baraldi et al. 
2006, Bodini et al. 2006, Hanazawa et al. 2000). Increased nitrotyrosine 
immunoreactivity has also been reported in the lung biopsies of asthmatics (Saleh et al. 
1998). It has been postulated that nitrotyrosine might play a major role in the 
pathogenesis of airway remodeling (Kharitonov and Barnes 2001a) and it may 
contribute to airway obstruction and hyperresponsiveness and epithelial damage in 
asthma (Saleh et al. 1998). Abundant iNOS and nitrotyrosine positive sputum cells 
have also been seen in COPD patients when compared to healthy smokers with a 
negative correlation to FEV1 (Ichinose et al. 2000). However, also in the sputum 
samples of smokers without airway obstruction and also in some samples of non-
smokers one can detect increased levels of nitrotyrosine (Rytila et al. 2006). Although 
both HPLC technique and GC/MS are sensitive and provide similar nitrotyrosine levels 
in the EBC, they are not able to differentiate healthy controls from asthmatics, 
suggesting that nitrotyrosine may not be a selective marker for oxidative stress in 
asthma (Celio et al. 2006). It is also likely that nitrotyrosine is not useful in 
differentiating between asthmatic and cigarette smoke-related airway disease. 
 
7.1.2.3 S-Nitrothiosols 
 
Nitric oxide can be trapped by thiol containing biomolecules such as glutathione (GSH) 
to form S-nitrothiosols. These compounds are increased in the EBC of smokers and 
patients with asthma (Corradi et al. 2001) and the levels decrease with corticosteroid 
treatment in asthma (Kharitonov et al. 2002). However, the increase in the levels of the 
S-nitrothiosols in EBC is transient and most likely not sensitive enough to be of use in 
the diagnostic assessment of airway disease (Franklin et al. 2006).  
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7.1.3 Other exhaled markers of oxidative stress 
 
In addition to FeNO, several other gaseous markers suggesting increased oxidative 
stress in the airways have been studied both in asthma and COPD. 
 
7.1.3.1 Hydrogen peroxide (H2O2) 
 
Exhaled H2O2 has been detected in patients with stable COPD and during exacerbation 
phases (Dekhuijzen et al. 1996, Kharitonov 2004) with the levels being related to the 
disease severity and also in steroid-naïve asthmatics (Kharitonov et al. 2002). In 
healthy smokers, macrophages release more H2O2 than the cells from non-smokers 
(Baughman et al. 1986, Guatura et al. 2000, Nowak et al. 1996). Exhaled H2O2 
concentrations are higher in smoking than non-smoking asthmatics or controls, though 
there is high variability (Horvath et al. 2004). In addition, cigarette smoke evokes to an 
acute elevation in exhaled H2O2 levels in patients with asthma, suggesting that smoking 
causes additional release of ROS in the airways (Horvath et al. 2004). Comparison of 
the H2O2 results from different laboratories is difficult since there are several techniques 
to measure H2O2, all with their own limitations (Van Hoydonck et al. 2004). Overall, 
H2O2 is relatively unstable and its analysis is not sensitive or specific enough to permit 
the diagnosis, differential diagnosis or monitoring of COPD or asthma. 
 
7.1.3.2 Carbon monoxide (CO) 
 
Carbon monoxide (CO) is produced from the degradation of heme by hemeoxygenase 
or non-heme-related release from xenobiotics and bacteria. Approximately 85% of CO 
is exhaled (Barnes et al. 2006, Kharitonov and Barnes 2001a). Several pathological 
conditions other than airway inflammation can contribute to CO formation. It has been 
reported that exhaled CO levels are elevated in stable asthma and decrease near to the 
normal values by treatment with inhaled corticosteroids (Barnes et al. 2006, Horvath et 
al. 1998, Zayasu et al. 1997). Cigarette smoke has marked effects on exhaled CO, 
complicating the assessment in COPD. Although the analysis of CO is straightforward, 
the levels of CO are too variable for the clinical assessment of asthma and COPD, their 
diagnosis or follow-up. 
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7.1.3.3 Volatile organic compounds (VOCs) 
 
Many volatile hydrocarbons exist, but only a few of them have been analyzed, one of 
the most extensively investigated has been ethane. Increased exhaled ethane levels have 
been detected in patients with mild steroid-naïve asthma when compared to steroid-
treated asthmatics and healthy controls (Paredi et al. 2000a). It has also been reported 
that COPD patients have elevated exhaled ethane levels that correlate with the degree 
of airway obstruction (Paredi et al. 2000b). However, exhaled ethane levels increase 
also due to physical (Leaf et al. 1997) and mental stress and smoking (Habib et al. 
1995) perhaps due to the high concentrations of hydrocarbons and direct oxidative 
damage. Cigarette smoke contains ethane and in healthy smokers, a transient elevation 
of the exhaled ethane concentration has also been reported (Habib et al. 1995). In 
addition, measurement of ethane is demanding and difficult to use in clinical practice 
(Barnes et al. 2006, Larstad et al. 2002). The relative concentrations of the aldehydes 
are also different and do not correlate with each other when measured in EBC and 
induced sputum (Corradi et al. 2004). Several VOCs exist and combinations i.e. VOC 
profiles can be developed and assayed with modern small gas chromatographic 
techniques. The technique of the so-called electronic nose has been found to be a 
promising method in discrimininating the exhaled breath of patients with asthma from 
controls but it seems that it is less accurate in distinguishing asthma severity 
(Dragonieri et al. 2007). 
 
7.1.4 Markers of lipid peroxidation 
 
7.1.4.1 8-isoprostane 
 
Oxidative damage to lipids leads to the production of isoprostanes, which are 
prostaglandin analogues produced mainly by free radical-induced peroxidation of 
arachidonic acid (Morrow et al. 1990). The best-characterized isomer is 8-iso-
prostaglandin F2α (8-isoprostane), which is considered to reliably reflect the degree of 
oxidative stress in vivo– it is a stable metabolite and specific for lipid peroxidation 
(Cracowski et al. 2002, Janssen 2001, Morrow and Roberts 2002). Dietary fats do not 
have any significant effect on the 8-isoprostane concentrations (Gopaul et al. 2000). 8-
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Isoprostane has been proposed to represent a useful tool in exploring oxidative stress in 
lung diseases with high reliability (Montuschi et al. 2004). Several studies have 
reported that 8-isoprostane may be an important mediator of oxidative stress and 
pulmonary oxygen toxicity (Janssen 2001) and form part of a common pathway leading 
to airway obstruction (Paredi et al. 2002). Antioxidants may be able to scavenge ROS 
but it seems that they fail to decrease the rate of lipid peroxidation (Anderson et al. 
1988, Habib et al. 1999) perhaps due to the fact that only the first step of the 
complicated metabolic pathway of lipid peroxidation is initiated by free radicals 
(Morrow et al. 1990).  
 
Most studies have used commercial EIA (enzyme immunoassay) kits to detect 8-
isoprostane in EBC, this technique shows a good correlation with GC/MS (Antczak et 
al. 2002, Baraldi et al. 2003a, Battaglia et al. 2005, Biernacki et al. 2003, Kostikas et al. 
2003, Montuschi et al. 2000 and 1999, Simpson et al. 2005, Van Hoydonck et al. 2004), 
however there are some contradictory findings (Bodini et al. 2004, Rahman 2004, 
Simpson et al. 2005, Van Hoydonck et al. 2004). Increased EBC 8-isoprostane levels 
have been reported in children (Baraldi et al. 2003a and 2003b, Mondino et al. 2004, 
Shahid et al. 2005) and adults (Antczak et al. 2002, Battaglia et al. 2005, Montuschi et 
al. 1999) with asthma and COPD (Biernacki et al. 2003, Ko et al. 2006, Kostikas et al. 
2003, Montuschi 2000). The concentrations increase with asthma severity (Kharitonov 
and Barnes 2001a, Montuschi et al. 1999) and decline after treatment of acute asthma 
exacerbations though remaining higher than in healthy controls (Baraldi et al. 2003b). 
Smoking has been reported to cause an acute 50% increase in EBC 8-isoprostane levels 
within 15 minutes (Montuschi et al. 2000). No correlations have been found between 
EBC 8-isoprostane levels and age, sex, or history of smoking in pack-years (Montuschi 
et al. 2000). Furthermore, 8-isoprostane levels have not been found to associate with 
the dyspnea score, neutrophil count or lung function parameters (Montuschi et al. 
2000). 
 
Major limitations still exist in the detection of 8-isoprostane in the EBC, the 
concentrations are variable and often remain below the detection limit in the analysis 
(Van Hoydonck et al. 2004). This might be explained by the extensive dilution that 
occurs from water vapour during condensation and the low concentrations that are close 
to the detection limits of the EIA measurements (Effros et al. 2005). Several 
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confounding factors such as smoking, diurnal variation, age, alcohol consumption, 
caffeine and possibly also a diet rich in antioxidants have to be taken also into 
consideration. Many studies have also reported a major variation in the levels of 8-
isoprostane in non-smokers and smokers, suggesting that the commercial assay itself is 
variable. When one examines the earlier and more recent studies, then it seems that 
EBC 8-isoprostane may not be either a very sensitive or a specific biomarker of 
oxidative stress given the variability in its measurement. 
 
The levels of 8-isoprostane are higher in sputum than in EBC (Mazur et al. 2009, 
Simpson et al. 2005). Sputum 8-isoprostane levels are elevated in COPD and cigarette 
smokers, but do not clearly differentiate healthy smokers from symptomatic smokers 
i.e. those who are at risk of developing COPD (Kinnula et al. 2007). It is important that 
8-isoprostane was elevated in smokers without COPD reflecting oxidative stress 
already due to smoking alone, but in a cross-sectional setting, its relevance for COPD 
development could not be evaluated. The level of 8-isoprostane in sputum is elevated 
also in adults with stable asthma when compared to healthy subjects, increase further 
with disease severity and decrease significantly after treatment of an acute asthma 
exacerbation. However there is a wide variability in the 8-isoprostane concentrations 
between and also within groups (Paredi et al. 2002). Overall 8-isoprostane is elevated in 
the sputum samples of smokers, subjects with COPD and asthma. 
 
7.1.4.2 4-hydroxy-2-nonenal (4-HNE) 
 
During lipid peroxidation, aldehydes are generated endogenously and they may be 
involved in many pathophysiological events associated with oxidative stress in cells 
and tissues (Gutteridge 1995). 4-HNE is a highly diffusible and reactive end-product of 
oxidative stress-induced lipid peroxidation and can attack targets far from the original 
site of free radical generation (Esterbauer et al. 1991). It has been postulated that the 
degree of formation of 4-HNE in response to smoking may also contribute to the 
development of enhanced airspace inflammation in COPD (Rahman et al. 2002). 4-
HNE has been detected in lung biopsies of COPD patients (Rahman et al. 2002) but 
also in induced sputum samples of chronic smokers, irrespective of the lung function 
parameters or symptoms compared to non-smokers (Rytila et al. 2006). It seems that 
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the presence 4-HNE might indicate that oxidative damage has occurred, but it may not 
provide any specific insight into the pathogenesis of the airway disease and most likely 
it will not prove to be a sensitive or specific biomarker for assessing the severity of 
COPD or asthma. 
 
7.1.5 Antioxidants and antioxidant enzymes 
 
The oxidant/antioxidant equilibrium is disturbed in COPD and asthmatic patients due to 
the chronic inflammation, activation of inflammatory cells and/or oxidant producing 
enzymes and also because of the changes in the antioxidant defence of the lung. It is 
believed that the major low molecular weight antioxidant of human airway secretions is 
GSH (Cantin et al. 1987) but its maintenance in the epithelial lining fluid (ELF) is still 
poorly understood. Free GSH can be measured but most of the GSH is bound to 
proteins and this is difficult to measure. The levels of GSH have been investigated in 
airway secretions and BAL but it seems that they are neither sensitive nor specific for 
COPD or asthma.  
 
The first line defence enzymes against superoxide radicals include superoxide 
dismutases (SODs) like manganese SOD (MnSOD) and it has been suggested that 
MnSOD and extracellular SOD (ECSOD) may be impaired or changed in the airways 
of asthmatics and COPD patients (Comhair et al. 2005, Regan et al. 2011). Enzymes 
related to GSH synthesis/homeostasis have an important role in the antioxidant defence 
of human lung (Cantin et al. 1987) and have been found to decrease towards COPD 
severity. Numbers of studies suggest that combined profiles of antioxidant and 
detoxification enzymes and their post-translational modifications like oxidation, 
thiolation and S-nitrosylation may be potential indicators of the severity of oxidative 
stress in the airways.  
 
7.2 Matrix metalloproteinases (MMPs)  
 
Matrix metalloproteinases are a large family of proteolytic enzymes (over 30 MMPs 
have been characterized) that degrade the components of the extracellular matrix 
(Ohbayashi 2002). MMPs are involved in pulmonary remodeling processes in both 
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COPD and asthma (Kelly and Jarjour 2003, Parks and Shapiro 2001). Oxidative stress, 
mainly cigarette smoke associated oxidants, can trigger MMP activation (Kinnula 
2005a). MMPs can be measured in sputum specimens rather easily. Significant 
differences have been reported in the MMP profiles in COPD and asthma i.e. COPD 
patients have elevated levels of MMP-1, -8, -9 and -12 (Beeh et al. 2003, Culpitt et al. 
2005, Demedts et al. 2006, Elkington and Friedland 2006, Vernooy et al. 2004) when 
compared to asthmatics, non-smokers and non-symptomatic smokers and these changes 
may reflect different pathogenesis of these diseases (Culpitt et al. 2005). MMPs might 
have significance as additional biomarkers in COPD and or/asthma development and 
also in evaluating different COPD phenotypes since the emphysematous type of COPD 
most likely displays a different profile of MMPs than the disease with airway 
predominance. 
 
7.3 Other potential markers 
 
7.3.1 C-reactive protein (CRP) 
 
Pulmonary inflammation in COPD is associated with elevated acute phase protein 
levels in plasma and it is possible that these proteins could be useful in predicting risk 
of future COPD events (Dahl and Nordestgaard 2009). C-reactive protein is an acute 
phase plasma protein synthesized in response to general inflammatory episodes (Black 
et al. 2004, Pepys and Hirschfield 2003). CRP is produced mostly in hepatocytes but 
also in adipocytes (Ouchi et al. 2003) and cultured coronary artery smooth muscle cells 
(Calabro et al. 2005). Although a major increase in CRP levels is seen in response to 
infection or tissue injury, a minor increase in CRP levels has been considered as a 
possible marker of disease in systemic conditions i.e. sensitive CRP (sCRP) (Ridker 
2001) and sCRP has indeed been detected by immunofluorescence in atherosclerotic 
plaques from human coronary arteries (Zhang et al. 1999). 
 
One study showed correlation between sCRP levels and pack-years of smoking and 
also in predicting mortality in patients with mild to moderate COPD in the short-term, 
although this correlation becomes weaker with time (Man et al. 2006). The same study 
demonstrated that high sCRP is associated with a yearly decrease in forced expiration 
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volume of habitual smokers and they suggested that combining the results of the sCRP 
assay and forced expiration volume would help to predict outcome and therefore enable 
early intervention. Dahl and co-workers measured sCRP levels in subjects with 
spirometry-defined airway obstruction i.e. subjects with a high risk of clinical COPD 
and during 8 years of follow-up, they found that subjects with higher sCRP levels at 
baseline had an increased cumulative incidence of COPD hospitalization and death 
(Dahl et al. 2007). However, in another study although there were significant 
differences in sCRP levels in the COPD patients, there was no difference in sCRP 
levels between smokers and non-smokers (Pinto-Plata et al. 2006). In a recent cohort 
study, sCRP was higher in COPD patients than in ex-smokers or non-smokers but 
showed wide variability over the 3 months of follow-up (Dickens et al. 2011). 
 
Most studies that have investigated sCRP levels in former smokers suggest that levels 
decrease slowly after smoking cessation (Hastie et al. 2008, Wannamethee et al. 2005, 
Lowe et al. 2001) indicating that the tissue damage caused by smoking takes some time 
to recover (Yanbaeva et al. 2007). A few longitudinal studies following sCRP levels 
before and after smoking cessation have also been undertaken (Crook et al. 2000, 
Hammett et al. 2007). In the study of Crook and co-workers (Crook et al. 2000) sCRP 
levels did not change significantly after 1 year and in the study of Hammett et al. 
(Hammett et al. 2007) after 6 weeks of smoking cessation.  Since sCRP has been 
connected not only to COPD but also to coronary artery disease (CAD) and 
atherosclerosis, it is clear that it is not a specific marker for COPD. Overall, the studies 
both on COPD and CAD suggest that sCRP is one marker of systemic inflammation in 
both disorders. 
 
7.3.2 Fibrinogen 
 
Fibrinogen is one of the acute phase proteins and its value in predicting future COPD 
has been evaluated in a few studies (Dahl et al. 2001, Gan et al. 2004). In the study of 
Dahl and co-workers, individuals with higher baseline plasma fibrinogen levels had 
reduced lung function, increased cumulative incidence of COPD hospitalization and an 
increased risk for COPD hospitalization during 6 years of follow up (Dahl et al. 2001). 
Gan et al. also reported a clear difference in plasma fibrinogen between COPD patients 
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and controls (Gan et al. 2004). However, it has been claimed that fibrinogen has limited 
value in clinical practice due to its low predictive value for COPD (Dahl et al. 2001). A 
recent study measured several blood biomarkers in patients with COPD, ex-smokers 
and non-smokers at baseline and at 3 months and found that fibrinogen was one of the 
biomarkers that were significantly higher in COPD patients when compared to ex-
smokers and non-smokers (Dickens et al. 2011). The same study reported that 
fibrinogen was the most repeatable biomarker and exhibited a weak correlation with the 
dyspnea score, 6-minute walk distance and exacerbation rate in COPD patients. In 
conclusion, fibrinogen may be a useful biomarker according to studies conducted so 
far, but these will require further confirmation. 
 
7.3.3 Panels of serum markers  
 
One study investigated a platform of several potential COPD biomarkers in a 
hypothesis driven study in the serum of patients with severe COPD and controls using 
novel microarray platform (PMP) technology (Pinto-Plata et al. 2007). They identified 
30 biomarker clusters for COPD and from the 19 best predictive clusters, 2-3 
biomarkers were selected based on their pathophysiological profile and the statistical 
significance of the correlations towards clinically important end points was calculated. 
They found a good correlation between the selected panel of 24 biomarkers and FEV1, 
carbon monoxide transfer factor, 6-minute walk distance, BODE index and 
exacerbation frequency. They concluded that PMP technology may be useful in 
identifying potential biomarkers in COPD and that it may be possible to differentiate 
patients with COPD from smokers and non-smokers using panels of selected serum 
markers. In summary, this study used a group of COPD patients including all 
phenotypes with severe disease in one cross-sectional study why the most promising 
markers identified in that study will require future investigations. 
 
7.3.4 Tumour necrosis factor-α (TNF-α) 
 
TNF-α is the most widely studied cytokine of the TNF super family in COPD and was 
originally described as a factor produced by the endotoxin stimulated macrophages that 
causes hemorrhagic necrosis of tumors (Carswell et al. 1975). Increased levels of TNF-
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α have been reported in induced sputum and lung biopsy of COPD patients (Keatings et 
al. 1996, Mueller et al. 1996, Gan et al. 2004). A recent study investigated TNF-α 
serum levels in healthy heavy smokers and healthy non-smokers (Petrescu et al. 2010). 
They reported significantly higher TNF-α serum levels in smokers when compared to 
non-smokers, and in addition a further increase of TNF-α serum levels in patients who 
had daily smoke exposure from smoking more than 1 pack/day. Thus, it has been 
claimed that the serum level of TNF-α may be a useful biomarker for the selection of 
heavy smokers with a high risk to develop smoke induced COPD (Petrescu et al. 2010). 
TNF-α is however one marker of systemic inflammation, and may thus also be 
associated with other diseases in addition to COPD. 
 
8. Non-biased Proteomics 
 
8.1 Proteomic studies on COPD/smokers 
 
Non-biased proteomics offers non-hypothesis driven approach to study disease 
biomarkers to airway diseases compared to healthy controls and/or to “healthy” 
smokers. This is particularly important in COPD where the activity of the disease is 
more difficult to evaluate when compared to asthma. Proteomics can be conducted for 
example from sputum, lung tissue, BAL or plasma/serum samples. BAL suffers from 
major problems for example its invasiveness and high dilution. Instead, serum contains 
several “contaminant” proteins, such as albumin and reflects systemic manifestations of 
other diseases as well. Sputum and lung tissue proteomics offer an interesting way to 
evaluate both airway and lung tissue protein profiles and can be assessed in more detail 
after the identified proteins have been characterized from both sputum and plasma 
samples. The most widely used proteomic technologies are two-dimensional gel 
electrophoresis (2DE), and the two- dimensional Difference Gel electrophoresis (2D-
DIGE) method representing a new and sensitive way to evaluate especially cysteine 
containing proteins; both of these techniques are usually combined with mass 
spectrometry to identify the changed proteins (Kinnula et al. 2009). To date, only a few 
proteomic studies have been conducted in the lung tissues of COPD patients (Ishikawa 
et al. 2010, Ohlmeier et al. 2008 and 2010). 
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Nicholas et al. investigated an induced sputum sample from one smoker using the 
combination of 2D gel analysis and GeLC-MS/MS and represented the first extensive 
survey of the proteome, with a total of 191 human proteins detected (Nicholas et al. 
2006). Another pilot-study studied induced sputum proteome profiles from healthy 
smokers, smokers with chronic bronchitis and smokers with COPD using CapLC-ESI-
Q/TOF-MS technique (Casado et al. 2007). A total of 203 human proteins were 
identified and clear differences were seen in the protein expression profiles related to 
the COPD phenotype and cigarette smoking illness severity. That particular study did 
not compare specific proteins between diseased and healthy samples, but assessed how 
often certain proteins could be detected, for example in COPD vs control specimens. It 
is possible that the proteomic approach might be useful in spotting specific and 
sensitive biomarkers associated to specific COPD stages and phenotypes. 
 
8.1.1 Surfactant protein A (SP-A) 
 
The initial proteomic studies reported highly elevated SP-A levels in the lung tissue 
samples of COPD patients (Ohlmeier et al. 2008). The finding is not surprising 
considering that SP-A is greatly associated with the protection of the lung. Pulmonary 
surfactant is a mixture of phospholipids and proteins formed mainly by type II 
pneumocytes (Kishore et al. 2006). SP-A and SP-D are members of the collectin family 
and have important and unique roles in pulmonary defence against 
inflammation/oxidative stress (Mason et al. 1998, Whitsett 2005). Surfactants have also 
been found to regulate the protease/antiprotease balance through different pathways, it 
has been proposed that SP-A might even regulate MMP-9 production and function 
(LeVine et al. 2000, Ramadas et al. 2009, Vazquez de Lara et al. 2003, Wert et al. 
2000). The exact mechanism leading to increased serum levels of surfactant proteins is 
unresolved but currently the most widely accepted hypothesis is that they are 
translocated from the lung into the circulation due to the changes in the alveolar-
capillary permeability (Hermans and Bernard 1999). Elevated plasma/serum SP-A 
levels have been earlier reported in smokers and patients with COPD in several studies 
(Behera et al. 2005, Kida et al. 1997, Kobayashi et al. 2008, Nomori et al. 1998, Robin 
et al. 2002). A proteomic study of pulmonary tissue conducted by Ohlmeier et al. 
revealed increased SP-A in COPD but not in the fibrotic lung (Ohlmeier et al. 2008). In 
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addition, a recent study reported elevated levels of both plasma and sputum SP-A in 
smokers without COPD when compared to non-smokers (Mazur et al. 2011). The same 
study investigated the effect of smoking cessation on plasma SP-A levels and found 
that after 2 years of follow-up, the SP-A level was significantly higher in those 
individuals who continued smoking compared to the quitters.  
 
Some opposite findings also exist about the circulating SP-A levels in smokers and/or 
COPD determined in serum (Mutti et al. 2006), lung tissue (Vlachaki et al. 2010) or 
BAL (Betsuyaku et al. 2004, Honda et al. 1996). However, some of the above 
mentioned studies on SP-A had been examined from BAL, which is somewhat 
problematic since it is invasive and also the risk of collapse of the airways in COPD, or 
by non-quantitative immunohistochemical technique. 
 
Age and genotype of the patient have been reported to influence the SP-A levels 
(Floros 2001, Tagaram et al. 2007) and some SP-A alleles might increase the risk for 
development of COPD (Guo et al. 2001). In the study of Ohlmeier and co-workers, SP-
A was confirmed to represent SP-A2 (Ohlmeier et al. 2008) but it is unclear if SP-A1 
and SP-A2 are related to smoking alone or if they can predict disease progression. 
 
8.1.2 Surfactant protein D (SP-D) 
 
In the proteomic study of Ohlmeier et al. (Ohlmeier et al. 2008) no change in SP-D 
levels were detected, neither could any change be seen between non-smokers, smokers 
or subjects with COPD could be seen in the lung tissue by Western blot analyses. 
However SP-D has been suggested to represent a marker for COPD and that it can 
especially predict COPD exacerbations (Lomas et al. 2009). The relationships between 
SP-D concentrations in serum and BAL are different in smokers or COPD patients 
when compared to allergic diseases like asthma (Winkler et al. 2011). In smokers and 
especially COPD patients have reduced levels of SP-D in BAL but elevated levels of 
SP-D in serum (Lomas et al. 2009, Winkler et al. 2011). It has been reported also that 
COPD patients receiving inhaled corticosteroid treatment have higher SP-D levels in 
BAL when compared to steroid-naïve COPD patients (Sims et al. 2008) and that 
treatment with oral corticosteroids decreases the serum SP-D levels in COPD patients 
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(Lomas et al. 2009). Winkler et al. reported that pulmonary and serum SP-D levels 
correlated even with the degree of airway obstruction in smokers and that cigarette 
smoke can disrupt SP-D’s quaternary structure which may impair its immunological 
function and increase the leakage of SP-D from the lung into the circulation (Winkler et 
al. 2011). However, in the study of Kobayashi and co-workers, the serum SP-D level 
was not changed in smokers (Kobayashi et al. 2008). In asthma or allergen induced 
airway inflammation, elevated levels of SP-D have been reported in both serum 
(Koopmans et al. 2004) and BAL (Erpenbeck et al. 2006). Overall, the role of SP-D in 
COPD has remained unclear. 
8.1.3 Polymeric immunoglobulin receptor (PIGR)  
 
The defence mechanisms of the lung include both cellular and humoral immune 
components. Secretory immunoglobulin A (SIgA) is the predominant Ig isotype in 
mucosal secretions and it acts as a scavenger i.e. prevents absorption and adherence of 
bacteria and viral agents (Pilette et al. 2001). Epithelial cells express specific receptors 
for polymeric Igs (pIgA and IgM) allowing their active transport into the mucosal 
lumen (Brandtzaeg et al. 1996). The polymeric Ig receptor (PIGR) can exist in several 
variants with different functions: full-length PIGR is associated with the transcytosis of 
IgA to mucosal surfaces while the cleaved form (secretory component, SC) together 
with polymeric IgA or as free form acts as a scavenge for environmental and microbial 
antigens (Kaetzel 2005, Wines and Hogarth 2006). PIGR is suggested to be a potential 
regulator of specific immune defence and inflammation (Wines and Hogarth 2006). 
SC/PIGR regulation is complex and dependent on several factors associated with 
COPD (Kaetzel 2005, Pilette et al. 2001, Ratajczak et al. 2010). 
 
At present, only a few studies have investigated the role of PIGR in COPD (Pilette et 
al. 2001, Polosukhin et al. 2011). Polosukhin et al. revealed a decline in the PIGR level 
in abnormal epithelium and airway remodeling areas in severe to very severe COPD 
(GOLD III-IV) (Polosukhin et al. 2011). In that particular study, total PIGR instead of 
SC was investigated. In addition, decrease of PIGR expression in airway epithelium 
was reported by Pilette and et al. in patients with very severe COPD (Pilette et al. 
2001). No studies have evaluated PIGR and its possible role in mild to moderate 
COPD.  
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8.1.4 Receptor for advanced glycation end products (RAGE)  
 
The receptor for advanced glycation end products (RAGE) is a transmembrane receptor 
belonging to the immunoglobulin superfamily (Neeper et al. 1992). Soluble RAGE 
(sRAGE) is an isoform of RAGE lacking transmembrane and cytosolic domains which 
acts as deception receptor for RAGE ligands in the extracellular matrix and it is 
postulated to be protective against inflammation and cell injury (Park et al. 1998). 
 
Smith et al. investigated sRAGE in plasma of COPD patients and reported that 
circulating sRAGE is lower in COPD when compared to healthy controls and shows a 
significant correlation to the degree of airway obstruction (Smith et al. 2011). Another 
study also reported significantly lower plasma sRAGE levels in COPD patients when 
compared to the control group including ex-smokers and current smokers and also a 
good correlation between sRAGE levels and the severity of emphysema (Miniati et al. 
2011). RAGE was also reported to be over-expressed in the airway epithelium and in 
the airway smooth muscle of smokers with COPD (Ferhani et al. 2010). 
 
Ohlmeier and co-workers investigated different RAGE isoforms in idiopathic 
pulmonary fibrosis (IPF) and COPD from lung tissue and BAL samples using 2-DE, 
MS and Western blotting (Ohlmeier et al. 2010). This study revealed a decrease of the 
full-length-RAGE (FL-RAGE) and its C-terminal processed variant (cRAGE) in the 
lung tissues of IPF and COPD patients, but endogenous secretory RAGE (esRAGE) 
was decreased only in IPF and unchanged in COPD. Another study also reported a 
decrease in RAGE levels in the lung tissue samples of IPF patients (Englert et al. 2008). 
Based on these studies, RAGE was not chosen for further investigations since it is not 
specific for COPD. 
 
8.1.5 Serum amyloid A (SAA)  
 
Serum amyloid A (SAA) is an acute phase protein induced by inflammatory mediators 
like IL-6, IL-1β and TNF-α and the levels rise during exacerbation phase of COPD 
(Sapey and Stockley 2006). SAA is secreted from the liver and of the four members of 
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the human SAA family, SAA1 and SAA2 are induced during inflammation or in 
response to tissue damage (Bozinovski et al. 2008). 
 
The study of Bozinovski et al. claimed that SAA was a novel candidate biomarker for 
COPD exacerbation by proteomic screening with SELDI-ToF (Bozinovski et al. 2008). 
Further measurements were conducted using the ELISA assay, which detects induced 
SAA1 and SAA2. They reported that the elevation of SAA is associated with an 
exacerbation severity and that it is more sensitive than CRP alone or combined with 
dyspnea. 
8.1.6 Lipocalin-1 
 
Lipocalin-1 is an innate defence molecule against microbes and has been shown to be a 
biomarker in tear fluid for several conditions including exposure to cigarette smoke (Xu 
and Venge 2000). Its main role is thought to be epithelial defence in the airways since 
its structure is similar to other antimicrobial proteins in the lipocalin superfamily and is 
widespread in the respiratory tract (Nicholas et al. 2010). 
 
In the recent sputum proteomic study of Nicholas et al. the levels of lipocalin-1 were 
elevated in healthy smokers when compared to non-smokers and they speculated that it 
may be due to either direct effects of cigarette smoke or an increased risk of smokers 
for bacterial infections (Nicholas et al. 2010). Surprisingly, in the same study, lipocalin-
1 was significantly reduced in the sputum of smoking COPD patients when compared 
to healthy smokers perhaps evidence of deficiencies in the innate epithelial defence, 
which might expose COPD patients to infectious exacerbations. They also reported a 
good correlation between lipocalin-1 and airway obstruction. However, there are no 
studies examining the role of lipocalin-1 in other lung diseases so it may not be 
sensitive or specific for COPD. 
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 AIMS OF THE STUDY 
 
The present study investigated potential non-invasive markers that reflect oxidative 
stress and cell defence in the airways of patients with COPD, asthma and smokers in 
order to find specific and sensitive markers for early diagnosis and differentiation of 
“healthy” smokers from the disease using different sample types. Another main topic 
was to assess the persistence of oxidative/nitrosative stress in the airways after smoking 
cessation. 
 
The aims of this study were 
 
- to assess the value of sputum and EBC 8-isoprostane in recently diagnosed children 
and adults with mild asthma 
 
- to compare oxidant markers in different sample types, such as sputum, plasma, 
exhaled air and lung tissue 
 
- to study the effects of smoking cessation on sputum neutrophils, 8-isoprostane, 
nitrotyrosine, matrix metalloproteinases (MMP-7, -8, -9) , TIMP-1 and FeNO in 
asymptomatic smokers and patients with chronic bronchitis/COPD or asthma. 
 
- to determine whether smoking and ageing affect the levels and relationships between 
plasma SP-A, SP-D, MMP-9 and TIMP1, which were selected based on previous 
studies on COPD suggesting that these markers may predict COPD, its development 
and/or progression 
 
- to seek new potential markers from sputum for early COPD using non-hypothesis 
driven non-biased proteomics 
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MATERIALS AND METHODS 
 
1. Materials 
1.1 Patient/subject characteristics 
 
The main characteristics of the study subjects are shown in Table 3. 
1.1.1 Study I  
 
Newly diagnosed asthmatic children, adults and healthy controls were included. 
Sputum samples, exhaled breath condensates (EBCs), FeNO and spirometry results of 
these study subjects were collected and received from the Helsinki University Central 
Hospital, Department of Allergology. The diagnosis of asthma was based on symptoms 
and on the bronchodilatation in spirometry, diurnal variation in PEF (peak expiratory 
flow) and/or significant improvement in PEF after a dose of bronchodilating medicine 
during home recording. In some cases, significant bronchial reversibility measured in 
exercise challenge test or histamine challenge test was used. The atopic status was 
assessed by skin prick tests for common aeroallergens and if there were one or more 
positive reactions, the patient was given a diagnosis of allergic asthma and the rest were 
considered as being non-allergic. Most of the subjects had allergic asthma. All patients 
started medication after the induced sputum had been collected.  
 
Patients with COPD exacerbation were included as a positive disease control for the 8-
isoprostane determinations. All the patients had airway obstruction with FEV1 of <80% 
predicted and the ratio of FEV1 to forced vital capacity (FVC) was <70 with no 
significant reversibility (GOLD criteria) (Pauwels et al. 2001) measured before the 
deterioration phase. All the patients had a history of chronic progressive symptoms and 
a long-term smoking history and half of them were still smoking. During exacerbations, 
the patients exhibited worsened lung function and the major symptoms increased. All 
patients or their parents gave full informed consent and the Ethics Committee of 
Helsinki University Hospital approved the study protocol. 
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1.1.2 Studies II and III 
 
In these prospective studies, subjects were recruited from three different smoking 
cessation clinics: Helsinki University Central Hospital (studies II, III), Southampton 
University Hospital (studies II, III) and the”Quitters” specialist smoking cessation 
service” of the Southampton and South West Hampshire Region (study II). The groups 
examined included asymptomatic smokers, smokers with chronic bronchitis (Stage 0 
COPD in earlier GOLD classification), smokers with varying severity of COPD, 
smoking asthmatics and non-smoking controls. Patients were advised to terminate 
smoking and the effects of smoking cessation on airway oxidative stress markers were 
investigated. In study II, fractional exhaled nitric oxide (FeNO), sputum 8-isoprostane, 
nitrotyrosine and matrix metalloproteinase-8 (MMP-8) were measured at baseline and 1 
and 3 months after successful cessation. Symptoms improvement was measured using 
the St Georges Respiratory Questionnaire (SGRQ). In study III, sputum neutrophils, 
matrix metalloproteinases (MMP-7, -8, -9) and tissue inhibitor of metalloproteinase-1 
(TIMP-1) were measured at baseline and at 3 and 6 months after cessation. Smoking 
cessation was confirmed by frequent exhaled carbon monoxide analyses. Lung function 
was measured using spirometry. All subjects gave full informed consent. The Ethics 
Committees of the Helsinki University Hospital and the Southampton University 
Hospital approved the studies. 
 
1.1.3 Study IV  
 
Plasma samples were collected from young non-smokers and smokers who were 
military draftees in the Northern Command of the Finnish Defence Forces (Hamari et 
al. 2010) and from middle-aged/elderly subjects who had been contacted from the 
Division of Pulmonary Medicine, Lapland Central Hospital (Toljamo et al. 2010). The 
study population included young healthy smokers and non-smoking healthy controls, 
middle-aged/elderly healthy smokers and non-smoking controls and patients with stable 
stage I-III COPD. All COPD cases were newly diagnosed. The diagnosis of COPD was 
defined according to the GOLD criteria (Pauwels et al. 2001). Lung function parameter 
tests included flow volume spirometry and single breath diffusion capacity. None of the 
subjects had any diagnosed disease or any medications.  
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1.1.4 Study V  
 
Sputum specimens of non-smokers, smokers and smokers with COPD were obtained 
from the area of Lapland Central Hospital (Toljamo et al. 2010). COPD was defined 
according to GOLD criteria (Pauwels et al. 2001) and only mild to moderate (Stage I-
II) cases were included. Smokers had a smoking history for at least 20 years, 
considered themselves as healthy and were not taking any medications. The study 
protocol was approved by the ethical committee of Lapland Central Hospital with 
written consent being obtained from each of the subjects. 
 
Lung tissue specimens were collected by lung surgery from patients treated in Helsinki 
University Central Hospital. Control tissues were obtained from lung surgery e.g. from 
hamartomas. The Ethics Committee of the Helsinki University Central Hospital 
approved the study and all patients received written information and gave their consent 
to use the samples. 
 
Plasma samples were received from non-smokers, smokers and smokers with COPD 
(stage I-II) from the area of Lapland Central Hospital. Smokers had a smoking history 
at least 20 pack-years, were healthy and were not taking any medications. The study 
protocol was approved by the ethical committee of Lapland Central Hospital with 
written consent being obtained from each of the subjects. 
 
2. Lung function measurement 
 
Standard spirometric measurements (Medikro M 904, Kuopio, Finland) were performed 
according to ATS/ERS recommendations (ATS/ERS 2005b). Reference values for 
Finnish population were used (Viljanen et al. 1982). 
 
3. Exhaled NO measurement 
 
The FeNO measurements (Niox, Aerocrine AB, Sweden) were performed according to 
ATS guidelines (ATS 1999). Expiratory airflow was 50 ml/s against a flow resistor. An 
exhalation time of 10 sec was used as a default, but in children less than 12 years old, 
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the exhalation time was allowed to be reduced to 6 sec, if needed. The mean value from 
a 3-second period from the end-exhaled NO plateau was recorded. At least three 
successive FeNO measurements were performed and the mean value was used for the 
analysis. 
 
4. Exhaled breath condensate (EBC) collection 
 
Exhaled breath condensates (EBCs) were collected according to the instructions of 
ATS/ERS; during tidal breathing using noseclip and saliva trap with a defined cooling 
temperature and collection time (ATS/ERS 2005a).  
 
5. Processing of the samples 
 
5.1 Sputum 
 
5.1.1 Sputum induction 
 
A standard procedure of induction was conducted using 4.5% hypertonic saline given at 
5-min intervals for a maximum of 20 min according to the guidelines of the European 
Respiratory Society’s Task Force (Djukanovic et al. 2002) in all centres.  
 
5.1.2 Sputum processing  
 
Sputum samples were processed immediately after induction. All sputum 
macroscopically free of salivary contamination was selected and treated with 
dithioerythritol (DTE, Sigma, Germany) and phosphate-buffered saline. The 
suspensions were filtered through 70-μm nylon gauze and centrifuged. The supernatant 
was stored at -80°C for biochemical analyses and immunoassay. The pellet was 
resuspended and the cell viability was studied by Trypan blue exclusion test. Coded 
cytospins were stained using May-Grunwald-Giemsa (MGG) method to obtain cell 
differential counts. At least 300-400 were counted on each slide. The slides were frozen 
at -20°C for further assays. The same researcher (Paula Rytilä) was involved in the 
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processing of the samples in Southampton and Helsinki. The same technician (Tiina 
Marjomaa) was involved in the teaching of how to process sputum in Helsinki and 
Rovaniemi. 
5.1.3 Sputum processing for proteomics 
 
For proteomics sputum supernatants processed as above were used. Protein 
concentrations were analyzed by the Dc Protein Assay kit –method (Bio-Rad, Hercules, 
CA). 
 
5.2. Tissue 
 
5.2.1 Paraffin blocks for immunohistochemistry 
 
Paraffin-embedded tissue sections were deparaffinized in xylene and rehydrated in 
graded alcohol. Antigens were retrieved by heating the sections in citrate buffer and 
endogenous activity was blocked using hydrogen peroxidase. 
 
5.2.2 Tissue homogenates for Western blotting 
 
Frozen tissue samples were homogenized in cold phosphate buffered saline (PBS) and 
adjusted to standard μg/ μl protein concentration. Protein concentrations were analyzed 
by the Dc Protein Assay kit –method (Bio-Rad, Hercules, CA). 
 
5.3 Plasma  
 
Peripheral venous blood was collected into EDTA tubes. Plasma was prepared by 
centrifugation for 10-15 min at 1500 × g and stored at - 80 C until analysed. 
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Table 3. Main clinical characteristics of the subjects of all studies. 
 
 
Subjects
 n
Male/
female
Age 
yrs
Pack 
years
FEV1
 (%pred)
Subject n 
in final analyses
Study I
Asthmatic children 23  15/8 10 93
Sputum
10
Asthmatic adults 14  2/12 38 84 10
Healthy children 13  5/8 11 101 8
Healthy adults 15  6/9 40 5 103 9*
COPD exacerbation 11  7/4 72 35 43  11**
Study II
Asymptomatic 
smokers 25  11/4 41 22 98
Baseline/ 1mo/3mo
25/3/3
Smokers with
chronic bronchitis/
COPD stage I-IV 21  7/14 56 39 77  21/6/6
Smokers with asthma 15  5/10 42 22 96  15/3/3
Non-smoking controls 33  27/6 58 4 99 4***
Study III
Asymptomatic
smokers 25  10/15 42 23 97
Baseline/3mo/6mo
25/6/4
Smokers with
chronic bronchitis/
COPD stage I-II 21  7/14 56 39 79  21/7/1
Smokers with asthma 15  6/9 42 22 99  15/4/4
Non-smoking controls 30  23/7 56 4 104 30****
Study IV
Young non-smokers 36  34/2 20  - 97
Plasma
36
Young smokers 51  50/1 20 5 100 51
Middle-aged 
non-smokers 40  12/28 5  - 105 40
Middle-aged smokers 64  40/24 52 30 95 64
COPD stage I-III 44  35/9 61 40 70 44
Study V (PIGR)
Sputum/plasma 
Healthy non-smokers  7/36 59/56  -
FEV1/
FVC %
88/86
Healthy smokers 72 53 29 82
COPD stage I-II  7/42 63/61 44/39 64/60  
 
Data are shown as means. 
* This group includes 2 ex-smokers who had stopped smoking ≥ 20 years before the 
study and 1 current smoker 
** This group includes 6 ex-smokers who had stopped smoking ≥ 10 years before the 
study 
*** This group includes 12 ex-smokers who had stopped smoking ≥ 20 years before the 
study 
**** This group includes 9 ex-smokers who had stopped smoking ≥ 20 years before the 
study 
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6. Methods 
 
6.1 Sputum staining for cell differential counts (Studies I, II, III) 
 
The cytospin slides were stained using May-Grunwald-Giemsa (MGG) method to 
obtain cell differential counts. At least 300-400 cells were counted on each slide. If the 
samples had less than 70% of squamous epithelial cells they were accepted for further 
assessments. 
 
6.2 Sputum proteomics (Study V) 
 
6.2.1 Two-dimensional Difference Gel Electrophoresis (2D-DIGE) 
 
Purified sputum (5 µg) from non-smokers, smokers, and smokers with COPD (Stage II) 
was labelled with the “CyDye DIGE Fluor labeling kit (“saturation DIGE”; GE 
Healthcare, Piscataway, NJ, USA) according to the manufacturer`s protocol. Proteins 
were separated by isoelectric focusing in immobilized pH gradient strips (pH 4-7, 24 
cm; GE Healthcare) with the Multiphor II system (GE Healthcare) followed by SDS-
PAGE in polyacrylamide gels (12.5%) overnight with the Ettan DALT II system (GE 
Healthcare). Fluorescence signals were detected with a Typhoon 9400 (GE Healthcare) 
and 2-D gels analyzed with Delta2D 4.0 (Decodon, Greifswald, Germany). 
 
6.2.2 Protein identification using mass spectrometry (MS) 
 
For protein identification, excised spots were digested and peptide masses were 
measured with a VOYAGER-DETM STR (Applied Biosystems, Foster City, CA, USA). 
Proteins were identified by full database search (Aldente database version 11/02/2008, 
[http://au.expasy.org/tools/aldente/] with the following parameters: 20 ppm; 1 missed 
cut; [M+H]; +CAM; +MSO). The expected spot position in the 2D-gel according to the 
known protein sequence was calculated with the Compute pI/Mw tool 
(http://ca.expasy.org/tools/pi_tool.html). 
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6.3 Western blot analysis (Study V) 
 
The sputum and tissue samples were loaded to polyacrylamide gels. Electrophoretic 
separation of proteins was done at 100V for 1 hour and the protein bands were 
transferred to nitrocellulose membranes using a Mini Trans-Blot Electrophoretic 
Transfer Cell (Bio-Rad, Hercules, CA). Membranes were blocked overnight in 10% 
skimmed milk in Tween-TBS. The membranes were probed with anti- PIGR antibody 
followed by secondary antibody treatments. Ponceau S staining was used to standardize 
the loading of the lung homogenate. For the Western blot of the sputum supernatants, 
equal volumes of the supernatants were loaded.  A chemiluminescent HRP-substrate 
immunodetection kit (Millipore, Billerica, MA) was used for immunodetection. 
Membranes were exposed to X-ray film (Kodak, Rochester, NY).  
 
6.4 Enzyme immunoassays (EIA)/Enzyme-linked immunosorbent assay (ELISA) 
(Studies I, II, III, IV, V) 
 
Sputum (Studies I, II) and EBC (Study I) 8-isoprostane concentrations were determined 
by a specific EIA kit (Cayman Chemical, Ann Arbor, MI, USA) with standard curves. 
Sputum/plasma MMP-7, MMP-8, MMP-9 and TIMP-1 (Studies II, III, IV) 
concentrations were analyzed by commercial ELISA kits (Amersham Biosciences, 
Cardiff, UK) according to the manufacturer’s instructions. Plasma SP-A and SP-D 
levels (Study IV) were measured by commercially available EIA/ELISA kits (SP-A test 
Kokusai-F kit, Sysmex, Kobe, Japan; SP-D kit Yamasa EIA kit, Yamasa Co.,Chiba, 
Japan). PIGR in plasma was analyzed by ELISA (E91074Hu, Uscn Life Science Inc., 
Burlington, NC, USA; according to the manufacturer`s instructions.  
 
6.5 Immunohistochemistry/morphometry (Study V) 
 
NovoLink polymer detection system (RE7150-CE, Novocastra Laboratories ltd, 
Newcastle Upon Tyne, UK) was used for immunostaining according to the 
manufacturer's instructions. Detection was performed with anti-goat secondary 
antibody. Negative control sections were treated with mouse isotype control (Zymed 
Laboratories, San Francisco, CA, USA) or PBS. Digital images of lung tissue sections 
63 
 
with normal looking lung histology by excluding the damaged areas, assessed by an 
experienced pathologist, were taken using 200 x magnification and saved as Photoshop 
JPG files. The areas of positively vs. negatively stained tissue were measured using 
Image Pro software (Media cybernetics, UK) 
 
7. Statistical analyses 
 
All the statistical analyses were performed using the SPSS (versions 10.0, 15.0 and 
18.0) software program (SPSS Inc., Chicago, IL, US). The data are given as median 
and range or means together with standard deviation (SD).  Data for all groups was 
analyzed by Kruskall-Wallis test and differences between individual variables from two 
groups were analyzed by the Mann-Whitney U-test, the analyses of variance (ANOVA) 
or t-test. All differences between two time points were analyzed by the non-parametric 
Wilcoxon signed rank test.  Correlations between variables were determined using the 
Spearman rank correlation test or with the Pearson correlation coefficient. Linear 
multivariate regression analysis was used to study the independent effect e.g. the effect 
of age on plasma SP-A levels. Receiver operating characteristic (ROC) curves were 
used to analyze if plasma SP-A has a predictive capability to distinguish the healthy 
subjects from the patients. P-value ≤ 0.05 (Studies I, II, III, V) or p < 0.01 (Study IV) 
was considered as statistically significant. 
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RESULTS 
 
1. FeNO, sputum eosinophils and 8-isoprostane in early mild asthma (Study I) 
 
FeNO and sputum eosinophils were increased in mild asthma 
FeNO levels were increased in asthmatic children and adults compared to healthy 
children (p<0.001) and healthy adults (p=0.025). Only 10/23 asthmatic and 8/13 
healthy children and 10/14 asthmatic and 9/14 healthy adults could produce suitable 
sputum specimens so the sputum biomarkers could not be analyzed from every 
participant. The percentages of sputum eosinophils did not change in asthmatic children 
compared to healthy children (p=0.52) but were highly significantly elevated in 
asthmatic adults compared to healthy adults (p<0.0001). Further, patients with COPD 
exacerbation (n=11) had a higher percentage of eosinophils than healthy controls 
(p=0.005). A good correlation was found between FeNO and eosinophils (R=0.65, 
p<0.0001) calculated between all groups. 
 
Sputum 8-isoprostane was not elevated in mild early asthma 
Sputum 8-isoprostane levels overlapped widely between the healthy and asthmatic 
subjects and there was extensive variation in the 8-isoprostane levels within the study 
groups. 8-Isoprostane was detectable in all healthy children and adults but the levels did 
not differ from those in asthmatic children (p=0.90) or adults (p=1.00) with recent 
asthma. No correlations were found between 8-isoprostane levels and FEV, FEV1/FVC 
or sputum eosinophils. Patients with COPD exacerbation, which were used as positive 
controls, had significantly elevated sputum 8-isoprostane levels when compared to 
healthy adults (Figure 2).  
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Figure 2. The mean sputum 8-isoprostane levels (pg/ml) in asthmatic and healthy 
subjects and patients with COPD exacerbation. There was no significant differences in 
8-isoprostane levels between asthmatic and healthy subjects but levels were highly 
elevated in patients with COPD exacerbation compared to healthy adults (p<0.05). 
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2. Effects of smoking cessation on oxidant markers in sputum and exhaled air 
(Studies II, III) 
 
2.1 Study II 
 
Oxidative markers were elevated in smokers at the baseline 
The baseline values of the FeNo, sputum 8-isoprostane, nitrotyrosine and MMP-8 were 
significantly lower (p<0.001 for each marker) in non-smokers (n=33) than in smokers. 
However, the markers did not differ significantly between the asymptomatic smokers 
(n=25), smoking asthmatics (n=15) or smokers with chronic bronchitis/COPD (n=21).  
 
Symptoms decreased in smokers who succeeded to quit smoking 
Of the total of 61 subjects, only six smokers with bronchitis or COPD (one with 
previous GOLD Stage 0 and five with Stage I-II COPD), six subjects with asthma and 
three asymptomatic smokers succeeded in quitting smoking for 3 months. Symptoms 
assessed by the St Georges Respiratory Questionnaire (SGRQ) improved significantly 
in these subjects (Table 4). The final analyses were conducted on the quitters who also 
had produced good quality sputum specimens (n=15). Spirometry values (FVC, FEV1, 
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FEV1/FVC) did not change significantly after smoking cessation when compared to 
baseline in any of the groups. 
 
Table 4. Symptoms score decreased significantly (a decrease of more than four points) 
in the quitters assessed by the St Georges Respiratory Questionnaire (SGRQ). 
 
Baseline 1 mo 3 mo
Symptoms score 47 16 26
Activity score 39 18 18
Impact score 19 4 14
Total score 30 10 21
 
 
The data are shown as means. Symptoms score addresses the frequency of respiratory 
symptoms, activity score measures disturbances to daily physical activity and impact 
score covers a range of disturbances of psycho-social function. Total score summarises 
the impact of the airway disease on overall health status. 
 
Neutrophils increased in chronic bronchitis/COPD after smoking cessation 
In the group of chronic bronchitis/COPD, the percentage of sputum neutrophils 
increased significantly after 3 months of smoking cessation (p=0.046) but in the 
asymptomatic smokers and asthmatics, the cell counts remained similar.  
 
Only 8-isoprostane declined significantly after smoking cessation 
The results of the subjects who succeeded in quitting of smoking were combined into 
one analysis. Sputum 8-isoprostane declined significantly during the follow-up at 3 
months (p=0.035), but levels still remained significantly higher than in non-smokers. 
The levels of FeNO, nitrotyrosine and MMP-8 did not change significantly during the 3 
months after smoking cessation.  
 
2.2 Study III 
 
Of the total 61 subjects, 17 smokers stopped smoking for 3 months and nine managed 
for 6 months. Of these 17 individuals, six were asymptomatic smokers, four had mild 
asthma and seven were suffering from chronic bronchitis or COPD (one with previous 
GOLD Stage 0 and six with Stage I i.e. mild COPD). Four asymptomatic smokers, four 
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asthmatic individuals and one subject with COPD succeeded in quitting smoking for six 
months. In the MMP analyses, these three groups were assessed as a single group.  
 
Inflammatory markers were increased in smokers at the baseline 
In the smokers, baseline induced sputum neutrophils, MMP-7, -8, -9 and TIMP-1 were 
significantly higher compared to non-smokers (n=30) (p=0.021, p=0.014, p=0.001, 
p=0.02, p=0.006, respectively).  
 
Neutrophils decreased to the levels of non-smokers after 6 months of smoking 
cessation 
The sputum neutrophil numbers increased significantly at 3 months after smoking 
cessation (p=0.035), but at 6 months the difference from non-smokers was no longer 
statistically significant.  
 
Sputum MMP-9 remained elevated after 6 months of smoking cessation 
The individual levels of MMP-7, -8 and TIMP-1 at 3 months after cessation did not 
change significantly from the corresponding baseline levels but after 6 months, the 
levels decreased significantly near to the levels of non-smokers compared to the 
baseline (p=0.032, p=0.001, p=0.04, respectively). In contrast, the individual levels of 
MMP-9 increased significantly from the baseline at 3 months after cessation (p=0.009) 
and did not differ significantly at 6 months after the cessation when compared to the 
baseline levels in these same individuals (p=0.069), and the differences were even more 
significant when compared to the non-smokers in a cross-sectional evaluation 
(p=0.017) (Figure 3).  
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Figure 3. The mean levels of sputum MMP-9 in the non-smokers and smoking 
cessation group at the baseline and at 3 and 6 months after stopping smoking. MMP-9 
levels remained elevated after 6 months of smoking cessation when compared to the 
levels of non-smokers (p=0.017).  
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3. Differences in potential markers related to smoking and COPD in young and 
middle-aged/older subjects in plasma samples (Study IV) 
 
Plasma SP-A increased with age and was elevated in smokers and patients with 
COPD 
Studies on plasma SP-A levels were based on a recent proteomic study by Ohlmeier 
and coworkers (Ohlmeier et al. 2008). This particular study was focused on plasma SP-
A, since the number of the sputum samples was not representative. Recently the levels 
of SP-A were found to be elevated in a small number of samples analyzed by the 
Western blot technique. In this particular study, plasma levels of SP-A by EIA 
increased with age in non-smokers and smokers (p < 0.0001 and p < 0.0001). Older 
smokers (n=64) had higher levels than young smokers (n=51) which might be related to 
their longer smoking history. In the young age group, there was no significant 
difference between non-smokers (n=36) and smokers. In the older age group, the 
plasma concentration of SP-A was higher in smokers when compared to non-smokers 
(n=40) (p < 0.0001). Importantly, plasma SP-A levels were also higher in COPD 
patients (n=44) compared to older smokers (p = 0.009), and non-smokers (p < 0.0001) 
(Figure 4). The linear regression analysis revealed that age (regression coefficient (B) = 
6.01, standard error (SE) = 2.54, p = 0.019), cigarette smoking (B = 0.45, SE = 0.07, p 
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< 0.001) and COPD (B = 17.08, SE = 3.67, p < 0.001) had independent effects on the 
SP-A level. 
 
Figure 4. The mean plasma levels of SP-A in young non-smokers (YNS), young 
smokers (YS), middleaged/elderly (old) non-smokers (ONS), middleaged/elderly (old) 
smokers (OS) and patients with stable stage I-III COPD. Plasma SP-A increased with 
age in non-smokers and smokers (p<0.0001 and p<0.0001). Plasma SP-A was higher in 
OS when compared to ONS (p<0.0001) and was also higher in COPD when compared 
to OS (p=0.009) and ONS (p<0.0001). 
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Plasma SP-D did not change with age but was increased in older smokers and in 
COPD 
The mean levels of plasma SP-D were similar in young and old non-smokers and did 
not change with age. Furthermore, there was no difference between young non-smokers 
and smokers. In the older group, plasma SP-D levels were higher in smokers and 
patients with COPD when compared to non-smokers (p = 0.012 and p < 0.0001) but 
there was no significant difference between COPD and smokers. COPD patients had 
even higher levels of plasma SP-D (B = 64.72, SE = 19.53, p = 0.001) when adjusted 
for age in the linear multivariate regression analysis. 
 
Plasma MMP-9 did not change with age but was elevated in older smokers and in 
COPD 
Protease/antiprotease imbalance and especially MMP-9 has been widely associated 
with COPD and its pathogenesis (Beeh et al. 2003, Gadek and Pacht 1990, Ilumets et 
al. 2007). The mean plasma levels of MMP-9 were very similar in young and old non-
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smokers and there was no significant difference between young non-smokers and 
smokers. Older smokers and COPD patients had significantly higher plasma MMP-9 
levels when compared to old non-smokers (p < 0.0001 and p=0.033). Linear regression 
analysis revealed that both age (B = 0.44, SE = 0.19, p = 0.022) and cigarette smoking 
(B = 26.0, SE = 6.91, p < 0.0001) had independent effects on the plasma MMP-9 level. 
 
Plasma TIMP-1 declined with age and MMP-9/TIMP-1 increased in smokers and 
COPD with long-term smoking history 
The plasma level of TIMP-1 declined with age (p = 0.03). No significant difference was 
detected between young non-smokers and smokers. In the older group, the TIMP-1 
plasma levels were higher in smokers and COPD patients than in non-smokers, but no 
significant difference was seen between smokers and the COPD subjects. The ratio of 
plasma MMP-9 to TIMP-1 did not change with age. In the young group, no difference 
was seen between non-smokers and smokers. In the older group, the plasma MMP-
9/TIMP-1 ratio was higher in smokers than in non-smokers indicating a significant 
protease/antiprotease imbalance in favor of proteases. The linear regression analysis 
confirmed the independent effect of smoking on MMP-9 (B = 16.18, SE = 6.66, p = 
0.018) and MMP-9/TIMP-1 (B = 4.01, SE = 0.15, p = 0.014). 
 
Especially plasma SP-A was related to age, smoking and lung function 
Clear positive linear correlations were observed between plasma SP-A levels and age 
and pack years and negative correlation between SP-A and lung function and some 
correlations were observed also with SP-D. The levels of SP-A correlated also with 
those of SP-D (r=0.36, p <0.0001). The plasma MMP-9 levels correlated only with age 
and pack years. 
 
Receiver Operating Characteristic (ROC) curve analysis is most accurate for  
SP-A 
ROC curve analysis was used to evaluate the sensitivity, specificity and diagnostic 
accuracy of plasma levels of SP-A, SP-D, MMP-9 and TIMP-1 in distinguishing 
patients with COPD from the control subjects. The areas under the ROC curve were as 
follows: for SP-A: 0.845 (95% confidence interval (CI), 0.787 to 0.902, p < 0.001); for 
SP-D: 0.734 (95% CI, 0.636 to 0.883, p < 0.001); for MMP-9: 0.551 (95% CI, 0.450 to 
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0.652, p = 0.320) and for TIMP-1: 0.664 (95% CI, 0.516 to 0.813, p = 0.051). Based on 
this study, SP-A appeared to represent the most promising marker for COPD. 
 
4. Proteomics revealed elevated PIGR levels in sputum, lung tissue and plasma in 
smokers and COPD patients (Study V) 
 
Sputum samples from non-smokers, smokers and smokers with COPD revealed 15 
altered proteins 
Sputum samples were screened using 2D-DIGE method in order to find smoking- 
and/or-COPD-dependent changes. Significant changes (p≤0.05) including mainly 
COPD-dependent alterations were detected and further investigated by mass 
spectrometry. “Healthy” smokers displayed no specific changes when compared to non-
smokers but the signals for zinc-α-2-glycoprotein, long palate lung and nasal epithelium 
carcinoma-associated protein and transthyretin were significantly elevated in both 
smokers and COPD whereas that of α-1-antitrypsin was elevated in COPD indicative of 
its protective role against COPD (Eriksson et al. 1985). The polymeric immunoglobulin 
receptor (PIGR) was elevated in COPD and was selected for more detailed 
investigation since its role in COPD pathogenesis is poorly understood (Pilette et al. 
2001, Polosukhin et al. 2011). 
 
Cleaved PIGR form (secterory component, SC) was elevated in sputum samples of 
COPD patients  
Mass spectrometry analyses of the PIGR spots indicated that sputum PIGR is present in 
its SC form based on the detected amino acids. As observed in 2-DE, sputum PIGR was 
detected by Western blot at 86 kDa with the level being elevated in COPD when 
compared to non-smokers (p=0.01) indicating the presence of full (83 kDa) or mature 
(81 kDa) PIGR whereas the expected size of the SC is 64 kDa. Since PIGR can exist 
also as a glycosylated form altering its migration in the gel, this was investigated by 
PNGase F treatment. The deglycosylation resulted in a shift from 86 kDa to 60 kDa. 
These findings verify the presence of glycosylated SC.  
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PIGR/SC is localized in specific lung cells and elevated in subjects with COPD 
compared to smokers and non-smokers 
PIGR in lung tissue specimens was investigated by Western blot and 
immunohistochemistry. As in sputum, PIGR was detected by Western blot in tissue 
homogenates only in one band at 86 kDa, evidence for the presence of glycosylated SC. 
However, there were no significant differences in PIGR between the groups detected by 
Western blot of the lung tissue in contrast to sputum PIGR. Therefore PIGR was further 
investigated by immunohistochemistry and it was found to be extensively expressed in 
the epithelium and alveolar macrophages. Immunoreactivity of PIGR was further 
quantified by image analysis. Elevated PIGR levels were detected in the alveolar-
interstitial area in smokers and even more in COPD when compared to non-smokers 
(all p <0.0001). A significant difference was also observed between “healthy smokers” 
and subjects with COPD (p<0.0001). PIGR levels were also elevated in normal looking 
bronchial epithelium in smokers and patients with COPD when compared to non-
smokers (Figure 5). 
 
Plasma PIGR elevation in smokers and smokers with COPD correlated with 
airway obstruction 
Plasma samples from non-smokers, smokers, and smokers with COPD were 
investigated by ELISA to confirm the role of PIGR as a potential local or systemic 
inflammatory regulator. Smokers and smokers with COPD possessed significantly 
higher PIGR levels in plasma as compared to non-smokers (p<0.0001 and p<0.0001). 
Plasma PIGR levels correlated significantly with the extent of airway obstruction 
(correlation co-efficient r = 0.240, p = 0.006). 
 
Sputum amylase and cystatin-S were decreased in COPD compared to the 
smokers and non-smokers 
Proteomics revealed decreased levels of amylase and cystatin-S in COPD when 
compared to the smokers and non-smokers. However, there was no difference in 
plasma amylase levels between groups when evaluated using ELISA.  
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Figure 5. PIGR was widely expressed in the bronchial epithelium. Specific localization 
of PIGR (brown color) is indicated by arrows. A) Non-smoker B) Smoker C-D) COPD. 
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DISCUSSION 
 
1. FeNO and sputum eosinophils were superior to 8-isoprostane in detecting early 
mild asthma 
 
Fractional nitric oxide (FeNO) is one of the few markers used in the clinical assessment 
and which can help in the diagnosis of asthma (Smith et al. 2005). Elevated FeNO 
levels have been documented widely in adults (Kharitonov et al. 1994, Persson et al. 
1994) and children (Byrnes et al. 1997, Lundberg et al. 1996, Nelson et al. 1997) with 
asthma, including mild and asymptomatic conditions (Alving et al. 1993, Kharitonov 
and Barnes 2001a) and the results of our study are in agreement with previous 
observations. FeNO is also sensitive to steroid treatment in asthma (Smith et al. 2005). 
Standardized measurements (ATS 1999) of FeNO correlate with eosinophilic airway 
inflammation and can predict the decline in asthma control (Kharitonov and Barnes 
2001b, Liu and Thomas 2005). Our study also found a good correlation between FeNO 
and sputum eosinophils. Sputum eosinophils were elevated in asthma, confirming that 
eosinophilic inflammation is a key feature of asthma.  
 
8-Isoprostane has been suggested to be a specific marker for lipid peroxidation (Janssen 
2001) and to be sensitive for evaluating oxidative/nitrosative stress in the airways. 
Increased levels of 8-isoprostane have been previously measured in sputum samples of 
smokers and mild stable COPD (Kinnula et al. 2007) and moderate/severe asthma when 
compared to healthy controls (Wood et al. 2005), although levels have been highly 
variable. Our study was the first to measure 8-isoprostane in sputum specimens with 
FeNO in asthmatic children and adults. We found a wide overlap in the 8-isoprostane 
levels between the healthy and asthmatic subjects and also a wide variation within 
study groups. Wood and co-workers (Wood et al. 2005) reported elevated sputum 8-
isoprostane levels in asthmatic adults but there was also overlapping between groups 
and the patients had moderate/severe asthma. Most of our subjects had mild asthma that 
might explain this difference, but it is also possible that commercial EIA method for 8-
isoprostane may not be sensitive enough to assess mild oxidative stress. COPD patients, 
who were used as positive controls in 8-isoprostane analyses, had significantly elevated 
sputum 8-isoprostane levels when compared to asthmatic and healthy adults which is in 
agreement with the previous findings (Kinnula et al. 2007). This might reflect the 
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increased oxidative stress boosted by neutrophils and their activation, which is a typical 
feature in airway inflammation in COPD (Hogg et al. 2004, Peleman et al. 1999). 
The power of this present investigation is reduced by two factors i.e. that patient 
material remained small and only some of the subjects could produce representative 
sputum specimens so the 8-isoprostane could only be analyzed from these subjects. 
This was also a cross-sectional study so longitudinal studies on the reproducibility of 8-
isoprostane in stable asthma are needed. 
 
Overall, it appears that while FeNO is sensitive in detecting oxidative stress even in 
mild asthma, sputum 8-isoprostane concentrations are highly variable and overlapping 
and do not detect mild asthma which might be due to low oxidant burden in the airways 
of asthma patients or due to the low sensitivity of the EIA method. In this particular 
study, an attempt was made to assess 8-isoprostane also in the EBC samples from mild 
asthmatics but most of the values were below the detection limit even though the 
samples had been concentrated. There was also a high variability both in and between 
the groups and no significant differences were seen between groups. However, the 
oxidant burden is high in the lungs of COPD patients and 8-isoprostane might be a 
better marker in this disease. 
 
2. Oxidant and protease burden persists in the airways for several months after 
smoking cessation 
 
Most of the previous smoking cessation studies have been cross-sectional and the real 
effects of smoking cessation on airway remodeling processes/tissue destruction have 
remained unclear. These present studies (II and III) revealed that oxidative stress can 
persist for months after the patient has stopped smoking. In study II, the neutrophil 
counts increased in COPD after three months of smoking cessation which is in 
agreement with previous results (Willemse et al. 2005). It seems that study III was the 
first prospective study to examine how smoking cessation influences the levels of 
sputum MMPs. It was found that sputum MMP levels generally decline slowly after 
smoking cessation. However, the levels of MMP-9 remained elevated in smokers at six 
months after giving up smoking for unknown reasons. 
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Smoking cessation is the most effective therapeutic intervention in smokers, especially 
in patients with COPD and asthma (Scanlon et al. 2000). Cessation success rates are 
generally low to moderate despite major efforts in developing efficient cessation 
programs and drugs to ease the withdrawal process (Aveyard et al. 2007, Gorecka et al. 
2003, Lancaster and Stead 2005). In the present studies, 25% (Study II) and 15% 
(Study III) of the smokers succeeded in quitting smoking at least for the duration of the 
follow-ups. This remarkable number of dropouts was anticipated when one considers 
the well-known difficulties of quitting smoking. However, these success rates were 
rather good and close to the published results of programs involving COPD patients 
who had received active counseling (Stratelis et al. 2006). 
Smoking cessation reduces COPD morbidity, hospital admissions (Godtfredsen et al. 
2002) and COPD progression (Rabe et al. 2007). It is known that after smoking 
cessation, the decline in lung function suppresses slowly not until after 2-3 years 
(Burchfiel et al. 1995, Townsend et al. 1991). Smoking causes very similar airway 
pathology in subjects with COPD and asthma; the typical features are the recruitment of 
increased numbers of neutrophils into the airways and elevated oxidative stress 
(Chalmers et al. 2001). This was found in studies II and III. Smoking asthmatics suffer 
from greater symptom severity and increased exacerbation frequency (Siroux et al. 
2000), accelerated decline in lung function (Ulrik and Lange 2001) and impaired 
response to corticosteroids (Chalmers et al. 2002, Chaudhuri et al. 2003, Pedersen et al. 
1996). Smoking asthmatics are also a group which is often excluded from asthma 
studies, in order to avoid a major confounding factor i.e. the effects of cigarette smoke. 
 
Cross-sectional studies have reported elevated inflammatory indices in terms of 
neutrophils, eosinophils and macrophages in ex-smokers when compared to never 
smokers (Bhowmik et al. 2000, Rutgers et al. 2000, Turato et al. 1995, Yamamoto et al. 
1997), and a shift from CD4+ (T-helper) to CD8+ (T-suppressor) predominance in 
heavy smokers and COPD patients (Costabel et al. 1986, Gamble et al. 2007). Only a 
few prospective longitudinal studies have assessed long-term effects of smoking 
cessation (Chaudhuri et al. 2006, Willemse et al. 2005). There is published evidence 
that inflammation may persist in the airways after smoking cessation for at least for one 
or two years but it is unclear how long the inflammation actually continues, even if it is 
completely irreversible.  
77 
 
2.1 Study II 
 
Sputum 8-isoprostane declined significantly but the levels of FeNO, sputum MMP-
8 and nitrotyrosine remained elevated after 3 months of smoking cessation 
In the group of bronchitis/COPD the percentage of sputum neutrophils increased 
significantly after 3 months of smoking cessation. Although the subject number 
remained low and these results have to be interpreted with caution, this in agreement 
with the study of Willemse et al (Willemse et al. 2005), which reported high neutrophil 
counts one year after smoking cessation in asymptomatic smokers and COPD patients. 
This would seem to suggest that neutrophilic inflammation remains long after subjects 
have stopped smoking.  
 
Smoking alone increases levels of sputum 8-isoprostane when compared to non-
smoking controls (Kinnula et al. 2007). In the present study, there was extensive 
variability in the baseline levels of 8-isoprostane, especially in the group of asthmatics. 
When the results from the quitters in the three groups were combined, the levels of 
sputum 8-isoprostane in the individual subgroups declined significantly after smoking 
cessation, but still remained higher than in non-smokers. Overall, these results suggest 
that there is a clear tendency but no significant or immediate decline in the oxidative 
stress within the first months after smoking cessation when evaluated by sputum 8-
isoprostane.  
Previous studies have shown that FeNO levels decline in smokers (Kharitonov and 
Barnes 2001a, Rytila et al. 2006) but in stable COPD, FeNO does not seem to differ 
from normal values (Balint et al. 2001, Corradi et al. 1999, Kharitonov and Barnes 
2001a, Rutgers et al. 1999, Rytila et al. 2006). Since cigarette smoke decreases FeNO 
levels it could be speculated that FeNO would increase after smoking cessation. In this 
study, FeNO was highly variable in asthma, which might be caused by the severity of 
the disease or the extent of smoking but also the different doses of inhaled 
corticosteroids used during the study. FeNO values were also quite variable in the 
group of patients with bronchitis/COPD and did not change after smoking cessation. 
Since all the asthma patients were using inhaled corticosteroids but most of the COPD 
patients did not, it is difficult to compare these groups. However, the fact that FeNO 
levels did not change significantly suggests that oxidative/nitrosative stress continues 
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after 3 months of smoking cessation. It is good to keep in mind also that FeNO 
regulation is complex and many of the reactions associated with its changes in smoking 
asthmatics and COPD are still partly unclear.  
Nitrotyrosine has been proposed to play a major role in the pathogenesis of airway 
remodeling (Kharitonov and Barnes 2001a). There is evidence that nitrotyrosine 
positive sputum cells are elevated in healthy smokers when compared to never smokers 
(Rytila et al. 2006) with further increase in severe COPD (Ichinose et al. 2000). In the 
present study, there was no change in the number of nitrotyrosine positive sputum cells 
after smoking cessation at 3 months in the combined group which is in agreement with 
the results of other markers of oxidative/nitrosative stress. These results indicate that 
smoking cessation does not lead to any immediate changes in the oxidant burden in 
asthma or COPD.  
Matrix metalloproteinases degrade the components of the extracellular matrix 
(Ohbayashi 2002) and are involved in the pulmonary remodeling processes in asthma 
and COPD (Kelly and Jarjour 2003, Parks and Shapiro 2001). MMPs including MMP-
8, MMP-9 and MMP-12 have been linked to COPD (Elkington and Friedland 2006). 
Smoking and oxidative stress might enhance MMP activation i.e. it can be speculated 
that MMP levels might decrease after smoking cessation. In this present study sputum 
MMP-8 in the combined group showed some tendency to decline but extensive MMP-8 
variation was seen in individuals after 3 months of smoking cessation and the levels of 
MMP-8 remained much higher than in non-smokers during the follow-up. These 
findings are in agreement with the results of Ilumets et al. (Ilumets et al. 2007) where 
the levels of MMP-8 were higher in subjects with chronic bronchitis compared to 
asymptomatic smokers. These results suggest that there is a persistent imbalance in 
protease/antiprotease cascade lasting at least for months after smoking cessation.  
The finding that symptoms were alleviated already one month after smoking cessation 
despite the persistent neutrophilic airway inflammation and oxidative stress is 
important. This suggests that the clinical improvement might not correlate with 
objective assessment of asthma/COPD. It is possible that in subjects who managed to 
quit smoking, the assessment of symptoms was influenced by a positive perception of 
smoking cessation.  It also might be that these particular investigated markers may not 
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have real clinical importance in COPD since the complex mechanisms involved in 
COPD pathogenesis are still poorly understood. 
 
2.2 Study III 
 
Sputum MMP-9 remained elevated after 6 months of smoking cessation while 
other markers declined to the levels of non-smokers 
In this study, at the baseline setting, smokers with or without mild airway disease had 
neutrophil predominance and elevated levels of several MMPs in induced sputum 
samples when compared to non-smokers. This is in agreement with the previous studies 
reporting elevation of the levels of MMP-8, -9 and TIMP-1 in smokers and patients 
with COPD (Elkington and Friedland 2006, Ilumets et al. 2007, Vernooy et al. 2004). 
There is also evidence that the disease itself, not only smoking, results in elevated 
levels of MMPs (Babusyte et al. 2007, Demedts et al. 2006, Deshmukh et al. 2008). 
Subgroups were combined which was justified for several reasons i.e. the subjects were 
smokers without airway disease or the disease was mild. The phenomenon that smoking 
asthmatics develop airway neutrophilia as is the case in smokers and subjects with 
COPD, was found also in this study. The MMP levels were overlapping in smokers as 
expected. In addition, the differentiation of smoking asthmatics from patients with 
COPD and symptomatic smokers from mild COPD is indeed a major challenge since 
there is overlapping in the cell profiles and the diseases (Chalmers et al. 2001). The 
levels of MMP-9 increased from the baseline during the 3-6 months after smoking 
cessation, suggesting that even if an individual stops smoking, the extracellular matrix 
breakdown can proceed for several months. Sputum neutrophil proportions increased at 
3 months after smoking cessation but at 6 months, the difference from non-smokers 
was no longer significant. This could be interpreted that the MMP-9 elevation is not 
dependent on the numbers of neutrophils per se but might reflect increased MMP-9 
release since neutrophils are an important source of MMP-9. There are somewhat 
controversial reports about whether elevated levels of MMP-9 are associated with 
increased MMP-9 activity. The studies of our laboratory have demonstrated that 
elevated levels of MMP-9 are associated with increased MMP-9 activity in smokers, 
patients with Stage 0 COPD as well as during COPD exacerbations (Ilumets et al. 2007 
and 2008). However, in the study of Lowrey et al. (Lowrey et al. 2008) sputum MMP-9 
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levels but not MMP activity was elevated in smokers with COPD when compared to 
smokers without COPD. It is important to remember that the present results are only 
preliminary and further investigations are needed about the role and significance of 
MMP-9 after smoking cessation. 
 
All of the other markers; MMP-7, -8 and TIMP-1 though exhibiting extensive 
variability, did return to the levels of non-smokers after 6 months of smoking cessation, 
suggesting that the repair of tissue damage may have been initiated. This is in 
agreement with the study of Willemse et al. (Willemse et al. 2005) where the values of 
the inflammatory markers like macrophages and IL-8 decreased significantly in 
asymptomatic smokers after one year of quitting smoking. This seems to be the first 
study showing MMP-7 elevation due to smoking. Macrophages are the main source of 
MMP-7 and their expression is also upregulated in pulmonary epithelial cells in the 
presence of chronic infection, suggesting that MMP-7 might contribute to pulmonary 
immunity (Dunsmore et al. 1998) and that chronic inflammation in the airways 
decreases after smoking cessation. 
 
There are some important factors that have to be taken into consideration when 
evaluating these results. The most important limitation is the modest success of the 
smoking cessation in both studies (II and III). There were also differences in the 
success rates between groups; these may have been due to differences in smoking 
cessation programs, the use of smoking cessation aids and the intensity of counselling. 
Also, the quitters in the groups of asymptomatic smokers, smokers with asthma and 
smokers with chronic bronchitis/COPD were assessed as a single group, so the results 
cannot be generalized to any specific group. In study II, one limitation is the variability 
of the subjects and medications within the groups; subjects with symptoms of chronic 
bronchitis were included in COPD group and the use of inhaled steroids differed 
between groups. In addition, the levels of the oxidant markers varied within each group 
in both studies. Sapey et al. (Sapey et al. 2008) reported also extensive variability in 
sputum inflammatory/oxidant markers obtained from COPD patients. Unfortunately, 
these reduce the statistical power of our analyses.  
 
The present studies suggest that there is no major immediate decline in the oxidant 
burden after smoking cessation in COPD or asthma. Since there was extensive 
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variability between individuals in the measured markers, it is possible that some of 
these markers may predict which patients might develop further lung damage in 
contrast to those patients in whom the disease processes may arrest. Although these 
results are important, further investigations with larger numbers of subjects with 
different phenotypes of asthma and COPD are needed. 
 
3. Age affects to smoking related markers 
 
It was decided to investigate plasma levels of SP-A, SP-D, MMP-9 and TIMP-1 in 
young and middle aged/elderly smokers and in patients with COPD. These potential 
markers were selected since previous studies have suggested that these markers may 
predict COPD, its development and/or progression (Beeh et al. 2003, Kobayashi et al. 
2008, Ohlmeier et al. 2008, Sin et al. 2007). The main goal was to study whether 
smoking and ageing affect the levels and relationships between plasma SP-A, SP-D, 
MMP-9 and TIMP-1 since only a few studies have investigated the effect of age on 
these potential biomarkers. 
 
It was found that SP-A appeared to be the most promising marker for COPD; its levels 
were elevated after long-term smoking and a further increase was seen in COPD when 
compared to chronic smokers. There was also a good correlation between age, pack-
years and airway obstruction. Whether SP-A can be used as a marker for COPD or its 
development remains still unclear. No difference was seen in any of the investigated 
markers between young non-smokers and those smokers with relatively short smoking 
histories, normal spirometry results and no medications. 
 
The main finding was that plasma SP-A levels were elevated in smokers and in COPD; 
these are in agreement with previous studies though there are several controversial 
findings as well. Kobayashi et al. reported elevated plasma/serum SP-A in Japanese 
smokers and patients with COPD and many studies have also reported elevated SP-A 
levels in circulating blood in smokers when compared to non-smokers (Behera et al. 
2005, Kida et al. 1997, Mazur et al. 2011, Nomori et al. 1998, Robin et al. 2002). The 
finding that circulating levels of SP-A are elevated in smokers independently of the 
symptoms (Mazur et al. 2011) may indicate that damage has already occurred in the 
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lung or alternatively the elevation may be simply due to smoking itself. SP-A has also 
been shown to be elevated in the lung tissue of COPD patients (Ohlmeier et al. 2008). 
Some studies have presented opposite findings about circulating SP-A levels in 
smokers and/or COPD measured in serum (Mutti et al. 2006), lung tissue (Vlachaki et 
al. 2010) and BAL (Betsuyaku et al. 2004, Honda et al. 1996). 
 
There are controversial results about the significance of plasma SP-D in COPD as well. 
One study found that serum SP-D is significantly elevated in COPD exacerbations 
when compared to smokers and non-smokers (Lomas et al. 2009). However, some 
studies have reported that the serum SP-D level does not change in smokers/COPD 
(Kobayashi et al. 2008) and several BAL studies have indicated that the SP-D level is 
reduced in smokers (Betsuyaku et al. 2004, Honda et al. 1996, More et al. 2010) and in 
COPD (Sims et al. 2008). In this study, there was no difference in plasma SP-D levels 
between the young and old smokers and non-smokers nor was any difference between 
old smokers and COPD. This in agreement with the study of Ohlmeier et al. (Ohlmeier 
et al. 2008) showing no significant change in lung tissue SP-D in COPD patients. In 
conclusion, there was slight variability in plasma SP-D levels and perhaps some 
elevation due to smoking but no significant changes were seen as in the case with SP-
A. 
 
The amount of MMP-9 was increased in long-term smokers which is in agreement with 
the previous studies (Ilumets et al. 2007, Lim et al. 2000). Apparently, this was the first 
study to investigate the levels of MMP-9 and TIMP-1 in different age groups of non-
smokers and smokers. We found no difference in plasma MMP-9 or TIMP-1 between 
young non-smokers and smokers but old smokers and COPD patients had significantly 
higher MMP-9 and TIMP-1 levels when compared to old non-smokers. These results 
suggest that only long-term smoking (>10 years) increases both plasma levels of MMP-
9 and the ratio of MMP-9/TIMP-1, perhaps reflecting the greater systemic 
inflammation. However, several other MMPs and TIMPs exist i.e. the MMP-9/TIMP-1 
ratio alone does not really reflect the overall protease/antiprotease balance in the lung 
and it is still unclear if the changes in MMPs and in the protease/antiprotease balance 
predict COPD in the longitudinal perspective. 
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One important limitation of this study was the fact that this was a cross-sectional study, 
so the value of these biomarkers in COPD will require further prospective 
investigations. Another weakness was that in the young age group, most of the subjects 
were men. In the group of older subjects, the plasma SP-A level was significantly 
higher in women than in men but no difference was seen between genders in the levels 
of SP-D, MMP-9 or TIMP-1. Strengths of this study include the fact that none of the 
smokers or non-smokers had any other exposures and did not use any medications. 
COPD cases were newly diagnosed so they were not using any medications and were 
otherwise healthy. 
 
4. Proteomics reveals new potential markers for smoking and COPD 
 
In this study 15 altered proteins were identified in sputum samples of non-smokers, 
smokers and smokers with COPD. PIGR was selected for more detailed investigation 
since it is postulated to be a potential regulator of specific immune defence and 
inflammation (Wines and Hogarth 2006). The 2-D DIGE method was used which is a 
highly sensitive detection of cysteine-containing proteins and an internal standard for 
improved statistical analysis. The most important finding was that PIGR was elevated 
in smokers and in individuals with mild to moderate COPD and this elevation was not 
confined to lung cells but also detected in plasma suggesting that PIGR might play a 
role in the systemic inflammation associated with smoking and COPD. 
 
At the time of this study, only a few sputum proteomic studies on COPD had been 
conducted and these studies identified only four proteins; zinc-α-2-glycoprotein, β-
microseminoprotein (isoform PSP94), cystatin S and transthyretin (Casado et al. 2007, 
Nicholas et al. 2010). Nicholas and co-workers found no change in zinc-α-2-
glycoprotein in smokers/COPD while in the present study, this protein was elevated. In 
that same study, transthyretin levels were elevated in COPD as was found also in this 
present study. In both of the earlier studies, PSP94 levels were elevated in COPD but in 
this study, this protein was detectable only in COPD as compared to non-smokers. The 
differences in these studies might be explained partly by the differences in the study 
groups and the variations in the sputum protein levels in smokers. In addition a 
different proteomic approach was adopted. 
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The elevation in PIGR was first observed in sputum using 2-D DIGE but importantly 
now the elevated levels of PIGR could be confirmed by Western blot and 
immunohistochemistry/image analysis in lung tissue and by ELISA in plasma samples 
from smokers and COPD patients. Furthermore, PIGR levels were greatly elevated in 
the normal looking alveolar region in COPD when compared to smokers and non-
smokers. This suggests that the PIGR alteration might be associated with smoking and 
COPD, which is actually not surprising since PIGR has a role in mucosal immunity 
(Kaetzel 2005, Wines and Hogarth 2006). 
 
PIGR exists in several variants with different functions: full-length PIGR is associated 
with the transcytosis of IgA to mucosal surfaces while the cleaved form (secretory 
component, SC) together with polymeric IgA or as free form scavenges for 
environmental and microbial antigens (Kaetzel 2005, Wines and Hogarth 2006). The 
IgA levels did not differ significantly in smokers or patients with COPD in sputum 
according to 2-D DIGE assay so this suggests that PIGR is present as the free form 
rather than in a complex with IgA. In addition the finding that SC was glycosylated, 
which is required for free SC to bind to host and pathogenic factors (Kaetzel 2005), 
suggests that PIGR was present in its free form since binding of IgA to a specific SC 
domain is not dependent in glycosylation (Hamburger et al. 2004). Glycosylated SC has 
been shown to inactivate interleukin-8 (IL-8) (Marshall et al. 2001 and 2004), which is 
one of the many inflammatory cytokines associated with COPD (Aaron et al. 2010, 
Eickmeier et al. 2010). It could be proposed that the elevation of SC in mild to 
moderate COPD might represent a mechanism to decrease inflammation in the airways. 
In agreement with the present results, elevated SC levels have been reported in the 
sputum samples from subjects with asthma and cystic fibrosis (Marshall et al. 2004) 
further support for a potential involvement of SC in lung defence and inflammation.  
Polosukhin and co-workers reported that PIGR levels decreased in abnormal epithelium 
and airway remodeling areas in severe to very severe COPD (GOLD III-IV) 
(Polosukhin et al. 2011). In that study, no current smokers were included and total 
PIGR was investigated instead of SC. Pilette et al. also reported decreased SC 
expression in airway epithelium but again in very severe COPD (Pilette et al. 2001). 
These results and the present findings suggest that PIGR is initially elevated by 
smoking, inflammation and in early COPD but declines towards the end stage disease 
in the injured epithelium. SC/PIGR regulation is also complex and dependent on 
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several of the factors that have been associated with COPD (Kaetzel 2005, Pilette et al. 
2001, Ratajczak et al. 2010) and this might explain part of these differences. 
 
In summary, in the present study PIGR levels were elevated not only in sputum but also 
in lung tissue specimens and plasma samples of smokers and patients with mild to 
moderate COPD. A good correlation was also seen between the elevated plasma PIGR 
levels and airway obstruction in smokers and subjects with early stage COPD 
suggesting that PIGR might be involved in the systemic effects of this disease. Further 
longitudinal studies will be needed to clarify the role of PIGR in COPD with systemic 
inflammation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
86 
 
CONCLUSIONS 
 
Different potential markers that reflect oxidative/nitrosative stress in the lung were 
investigated in sputum, plasma and tissue samples in order to identify the most specific 
markers for early detection and monitoring of COPD and asthma and to permit the 
differentiation of the disease from the condition of the “healthy smoker”. The effects of 
smoking cessation on oxidative/nitrosative markers were also assessed. 
 
FeNO levels were significantly elevated in newly diagnosed children and adults with 
mild asthma compared to healthy controls. Sputum eosinophil numbers were also 
significantly elevated in asthmatic adults and in asthmatic children there was a non-
significant trend towards eosinophil increase, when compared to healthy controls. 
Patients with COPD exacerbation had higher eosinophil levels than healthy controls. 
The levels of FeNO and eosinophils correlated with each other, confirming the key 
roles of FeNO and eosinophils in asthma.  
 
Sputum 8-isoprostane levels were very variable and there was overlapping in the 
groups of patients with recent mild asthma and healthy subjects, while in patients with 
COPD exacerbation, the sputum 8-isoprostane levels were significantly elevated when 
compared to healthy subjects. These results suggest that sputum 8-isoprostane may not 
be sensitive in reflecting oxidant burden in mild asthma, but in COPD, where the 
oxidant burden is high, 8-isoprostane may be useful. 
 
Smokers had increased levels of all investigated markers in the smoking cessation 
studies (II and III); sputum 8-isoprostane, nitrotyrosine, neutrophil counts, MMP-7, -8, 
-9, TIMP-1 and FeNO when compared to non-smokers. After 3 months of smoking 
cessation, sputum neutrophils increased in patients with chronic bronchitis/COPD 
(Study II) and in the combined group of quitters (Study III) but at 6 months, the 
difference from non-smokers was no longer significant. The sputum 8-isoprostane level 
decreased significantly after 3 months but FeNO, nitrotyrosine and MMP-8 did not 
change during the 3 months of follow-up. However, the levels of MMP-7, -8 and 
TIMP-1 decreased after 6 months of smoking cessation although sputum MMP-9 
remained elevated after 6 months of quitting smoking, and this may contribute to the 
lung damage typically encountered in COPD. 
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Plasma level of SP-A appeared to represent the most promising marker for COPD 
among those markers that had been included in this study, since it was elevated in 
COPD and long-term smokers and correlated with lung function and pack-years. Long-
term smoking increased also the plasma levels of SP-D, MMP-9, TIMP-1 and the ratio 
of MMP-9/TIMP-1 but there were no correlations with the extent of airway obstruction, 
in contrast to the situation with SP-A. According to ROC curve analysis, plasma SP-A 
was the most sensitive and specific marker for COPD. 
 
Proteomic screening of sputum and lung tissue samples revealed PIGR elevation in 
smokers and patients with early stage COPD. The altered PIGR was characterized as 
the glycosylated secretory component pointing to a role of PIGR/SC in the regulation of 
the inflammation present in COPD pathogenesis. PIGR was elevated also in the plasma 
of smokers and patients with COPD and the increase correlated with the extent of 
airway obstruction, indicating that this protein may be involved in the systemic effects 
associated with COPD. 
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FUTURE PERSPECTIVES 
 
To date, there are no validated and reliable markers for early COPD diagnosis. Of 
various markers, FeNO has been the most widely used and shown to have clinical 
significance in asthma, e.g. in differential diagnosis and monitoring. Although it is 
increasingly recognized that COPD has more than one phenotype (for example airway 
or emphysema predominant disease), all the patients are treated similarly since these 
different phenotypes have not generally been evaluated separately in any clinical trial 
so far and there is no specific biomarker which can differentiate between these 
phenotypes. Combining the existent knowledge of oxidant markers in sputum 
specimens and expanding the methodology to new technologies such as proteomics will 
be needed to clarify disease mechanisms and develop novel therapies as well as being 
able to predict the prognosis with accuracy. 
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